Derma Sciences (DSCI) 10-K 15 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 14, 2016	Jun. 30, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	DERMA SCIENCES, INC.
Entity Central Index Key	892,160
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 174,229,000
Trading Symbol	DSCI
Entity Common Stock, Shares Outstanding		25,884,797

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014	[1]
Current Assets
Cash and cash equivalents	$ 15,814,205	$ 19,396,845
Short-term investments	25,003,990	55,996,000
Accounts receivable, net	8,145,589	8,758,034
Inventories	20,690,706	13,280,940
Prepaid expenses and other current assets	1,449,407	2,590,211
Assets of discontinued operations	0	814,277
Total current assets	71,103,897	100,836,307
Long-term equity investment	16,110,178	8,422,790
Equipment and improvements, net	4,129,208	3,614,439
Identifiable intangible assets, net	9,831,245	12,815,504
Goodwill	13,457,693	13,457,693
Other assets	147,934	143,733
Total assets	114,780,155	139,290,466
Current Liabilities
Accounts payable	2,473,056	3,675,940
Accrued expenses and other current liabilities	6,691,340	5,522,853
Liabilities of discontinued operations	4,371,010	2,312,457
Total current liabilities	13,535,406	11,511,250
Long-term liabilities	1,014,378	521,358
Deferred tax liability	1,804,516	1,693,194
Total Liabilities	$ 16,354,300	$ 13,725,802
Commitments and Contingencies (Note 16)
Stockholders’ Equity
Convertible preferred stock, $.01 par value; 1,468,750 shares authorized; issued and outstanding 73,332 at December 31, 2015 and December 31, 2014 (liquidation preference of $3,222,368 at December 31, 2015)	$ 733	$ 733
Common stock, $.01 par value; 50,000,000 shares authorized; issued and outstanding 25,876,870 at December 31, 2015 and 25,319,203 at December 31, 2014	258,769	253,192
Additional paid-in capital	234,943,291	228,341,542
Accumulated other comprehensive income	5,272,908	911,563
Accumulated deficit	(142,049,846)	(103,942,366)
Total Stockholders’ Equity	98,425,855	125,564,664
Total Liabilities and Stockholders’ Equity	$ 114,780,155	$ 139,290,466
[1]	Reclassified for discontinued operations. See note 3.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Convertible preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	1,468,750	1,468,750
Convertible preferred stock, shares issued	73,332	73,332
Convertible preferred stock, shares outstanding	73,332	73,332
Convertible preferred stock, liquidation preference	$ 3,222,368
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	25,876,870	25,319,203
Common stock, shares outstanding	25,876,870	25,319,203

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	[1]	Dec. 31, 2013	[1]
Net Sales	$ 84,474,284	$ 83,745,680		$ 79,710,980
Cost of sales	51,740,109	53,635,745		50,320,506
Gross Profit	32,734,175	30,109,935		29,390,474
Operating Expenses
Selling, general and administrative	51,430,091	50,846,895		41,945,599
Research and development	807,128	440,246		0
Restructuring and other charges	2,458,555	0		0
Total operating expenses	54,695,774	51,287,141		41,945,599
Operating loss	(21,961,599)	(21,177,206)		(12,555,125)
Other expense (income), net	649,779	(181,543)		(185,740)
Loss before income taxes from continuing operations	(22,611,378)	(20,995,663)		(12,369,385)
Income tax (benefit) provision	(2,244,715)	(151,048)		160,111
Net Loss from Continuing Operations	(20,366,663)	(20,844,615)		(12,529,496)
Loss from discontinued operations, net of taxes	(17,740,817)	(18,926,940)		(11,434,557)
Net Loss	$ (38,107,480)	$ (39,771,555)		$ (23,964,053)
Net loss per common share - basic and diluted
Continuing operations	$ (0.79)	$ (0.85)		$ (0.73)
Discontinued operations	(0.69)	(0.77)		(0.67)
Total net loss per common share - basic and diluted	$ (1.48)	$ (1.62)		$ (1.40)
Shares used in computing net loss per common share - basic and diluted	25,734,474	24,584,071		17,056,632
[1]	Reclassified for discontinued operations. See note 3.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014		Dec. 31, 2013
Operating Expenses
Net Loss	$ (38,107,480)	$ (39,771,555)	[1]	$ (23,964,053)	[1]
Other Comprehensive Income (Loss)
Foreign currency translation adjustment	(445,360)	(216,710)		(370,880)
Unrealized gain (loss) on equity securities, net of taxes of $2,880,683, $28,832 and $0	4,806,705	48,125		(137,860)
Total other comprehensive income (loss)	4,361,345	(168,585)		(508,740)
Comprehensive Loss	$ (33,746,135)	$ (39,940,140)		$ (24,472,793)
[1]	Reclassified for discontinued operations. See note 3.

Consolidated Statements of Com6

Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Unrealized gain (loss) on equity securities, net of taxes	$ 2,880,683	$ 28,832	$ 0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Total		Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other ComprehensiveIncome [Member]	Accumulated Deficit [Member]	Convertible Preferred Stock [Member]
Balance at Dec. 31, 2012	$ 93,711,193		$ 165,247	$ 132,163,083	$ 1,588,888	$ (40,206,758)	$ 733
Balance (in shares) at Dec. 31, 2012			16,524,723				73,332
Net loss	(23,964,053)	[1]	$ 0	0	0	(23,964,053)	$ 0
Foreign currency translation adjustment	(370,880)		0	0	(370,880)	0	0
Unrealized gain on investment	(137,860)		0	0	(137,860)	0	0
Shares withheld for minimum payroll taxes	(228,149)		0	(228,149)	0	0	0
Exercise of warrants and options, net of issuance costs	2,817,001		$ 5,568	2,811,433	0	0	$ 0
Exercise of warrants and options, net of issuance costs (in shares)			556,855				0
Vesting of restricted stock units	0		$ 1,210	(1,210)	0	0	$ 0
Vesting of restricted stock units (in shares)			120,957				0
Issuance of common stock	0		$ 45	(45)	0	0	$ 0
Issuance of common stock (in shares)			4,450				0
Stock-based compensation	5,320,896		$ 0	5,320,896	0	0	$ 0
Preferred stock reset (Note 11)	0		$ 1,401	(1,401)	0	0	$ 0
Preferred stock reset (Note 11) (in shares)			140,086				0
Balance at Dec. 31, 2013	77,148,148		$ 173,471	140,064,607	1,080,148	(64,170,811)	$ 733
Balance (inshares) at Dec. 31, 2013			17,347,071				73,332
Net loss	(39,771,555)	[1]	$ 0	0	0	(39,771,555)	$ 0
Foreign currency translation adjustment	(216,710)		0	0	(216,710)	0	0
Unrealized gain on investment	48,125		0	0	48,125	0	0
Shares withheld for minimum payroll taxes	(300,070)		0	(300,070)	0	0	0
Exercise of warrants and options, net of issuance costs	2,270,714		$ 3,516	2,267,198	0	0	$ 0
Exercise of warrants and options, net of issuance costs (in shares)			351,651				0
Vesting of restricted stock units	0		$ 1,191	(1,191)	0	0	$ 0
Vesting of restricted stock units (in shares)			119,084				0
Issuance of common stock	80,616,032		$ 75,000	80,541,032	0	0	$ 0
Issuance of common stock (in shares)			7,500,000				0
Stock-based compensation	5,640,230		$ 0	5,640,230	0	0	$ 0
Issuance of a warrant	129,750		0	129,750	0	0	0
Preferred stock reset (Note 11)	0		$ 14	(14)	0	0	$ 0
Preferred stock reset (Note 11) (in shares)			1,397				0
Balance at Dec. 31, 2014	125,564,664	[1]	$ 253,192	228,341,542	911,563	(103,942,366)	$ 733
Balance (inshares) at Dec. 31, 2014			25,319,203				73,332
Net loss	(38,107,480)		$ 0	0	0	(38,107,480)	$ 0
Foreign currency translation adjustment	(445,360)		0	0	(445,360)	0	0
Unrealized gain on investment	4,806,705		0	0	4,806,705	0	0
Shares withheld for minimum payroll taxes	(168,946)		0	(168,946)	0	0	0
Exercise of warrants and options, net of issuance costs	1,992,463		$ 4,042	1,988,421	0	0	$ 0
Exercise of warrants and options, net of issuance costs (in shares)			404,187				0
Vesting of restricted stock units	0		$ 1,535	(1,535)	0	0	$ 0
Vesting of restricted stock units (in shares)			153,480				0
Issuance of common stock (in shares)			7,500,000
Stock-based compensation	4,783,809		$ 0	4,783,809	0	0	$ 0
Balance at Dec. 31, 2015	$ 98,425,855		$ 258,769	$ 234,943,291	$ 5,272,908	$ (142,049,846)	$ 733
Balance (inshares) at Dec. 31, 2015			25,876,870				73,332
[1]	Reclassified for discontinued operations. See note 3.

Consolidated Statements of Sto8

Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Unrealized gain on investment, net of taxes	$ 2,880,683	$ 28,832
Issuance of common stock, issuance costs		5,633,968
Exercise of warrants and options, issuance costs	$ 188	$ 7,500	$ 45,368

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015		Dec. 31, 2014		Dec. 31, 2013
Operating Activities
Net loss	$ (38,107,480)		$ (39,771,555)	[1]	$ (23,964,053)	[1]
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of equipment and improvements	926,225		868,052		878,151
Amortization of identifiable intangible assets	2,984,259		3,075,244		2,842,885
Provision for bad debts	30,111		67,702		43,930
Provision for sales adjustments	221,244		34,508		38,257
Provision for inventory obsolescence	461,668		83,848		7,317
Loss on disposal of equipment	42,797		7,549		11,917
Deferred rent	(80,733)		288,812		(13,215)
Stock-based compensation	4,783,809		5,640,230		5,320,896
Deferred income taxes	(2,725,996)		14,905		132,156
Changes in operating assets and liabilities:
Accounts receivable	324,230		(1,437,555)		(266,828)
Inventories	(9,080,112)		2,613,940		(3,042,090)
Prepaid expenses and other assets	1,836,829		224,941		(666,865)
Accounts payable	(1,642,479)		679,922		574,347
Accrued expenses and other liabilities	4,603,046		1,602,319		901,038
Net cash used in operating activities	(35,422,582)		(26,007,138)		(17,202,157)
Investing Activities
Purchase of investments	(55,004,220)		(91,483,693)		(33,723,000)
Proceeds from sale of investments	85,996,230		50,478,000		14,477,000
Purchase of equipment and improvements	(1,811,325)		(1,732,523)		(695,776)
Purchase of intangible assets	0		(1,125,000)		(350,000)
Net cash provided by (used in) investing activities	29,180,685		(43,863,216)		(20,291,776)
Financing Activities
Proceeds from the sale of common stock, net of costs	0		80,616,032		0
Proceeds from exercise of stock options and warrants, net of costs	1,992,463		2,270,714		2,817,001
Payment of withholding taxes related to employee stock compensation	(168,946)		(300,070)		(228,149)
Net cash provided by financing activities	1,823,517		82,586,676		2,588,852
Effect of exchange rate changes on cash	835,740		178,937		(209,990)
Net (decrease) increase in cash and cash equivalents	(3,582,640)		12,895,259		(35,115,071)
Cash and cash equivalents
Beginning of year	19,396,845	[1]	6,501,586		41,616,657
End of year	15,814,205		19,396,845	[1]	6,501,586
Supplemental disclosures of cash flow information:
Issuance of a warrant in connection with licensing agreement	0		129,750		0
Acquisition of equipment and improvements by increasing accounts payable	114,289		0		0
Cash paid during the year for:
Interest	189		7,785		893
Taxes	$ 17,553		$ 80,940		$ 0
[1]	Reclassified for discontinued operations. See note 3.

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business [Text Block]	1. Description of Business Derma Sciences, Inc. and its subsidiaries (the “Company”) is a medical device company focused on two segments of the wound care marketplace: advanced wound care and traditional wound care products. The Company markets its products principally through direct sales representatives in the United States (“U.S.”), Canada and the United Kingdom (“U.K.”), and through independent distributors within other select international markets. The Company’s U.S. distribution facilities are located in St. Louis, Missouri and Houston, Texas. The Company utilizes third party distributors for distribution in Canada, Europe, Latin America, Asia and the Pacific. The Company has manufacturing facilities in Toronto, Canada and Nantong, China.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies 2015 2014 2013 Cost of sales $ (697,105) $ 421,525 $ 57,894 Other expense (income), net 977,419 (13,537) (198,615) Total $ 280,314 $ 407,988 $ (140,721) Exchange rate fluctuations of foreign currency denominated assets and liabilities associated with inventory are included in cost of sales, while all other such fluctuations are included in other expense (income), net. 250,000 11 14 14 38 32 29 Presentation of Financial Statements -Discontinued Operations 10 13 Income Taxes The Company measures and recognizes the tax implications of positions taken or expected to be taken in its tax returns on an ongoing basis. In 2015, 2014 and 2013, the Company had no unrecognized tax benefits or liabilities, and no adjustment to its financial position, results of operations or cash flows were required. The Company records interest and penalties related to tax matters within other expense (income), net on the accompanying Consolidated Statements of Operations. These amounts are not material to the consolidated financial statements for the periods presented. The Company’s U.S. tax returns are subject to examination by federal and state taxing authorities. Tax years prior to 2012 are no longer subject to federal examination. However, the Company's federal net operating losses for tax years 2001 through 2011 will remain subject to examination until the losses are utilized or expire. State tax years 2011 to 2015 remain open to examination by the various state jurisdictions in which the Company is subject to tax. Tax years prior to 2006, as well as the 2007 tax year, are no longer subject to examination in Canada. The U.K. tax returns prior to 2013 are no longer subject to examination. 3,990,571 3,531,561 3,082,221 2,185,161 1,853,187 1,741,742 Year Ended December 31, 2015 2014 2013 Excluded dilutive shares: Convertible preferred stock 73,332 73,332 73,332 Additional stock issuable related 49,782 49,782 49,154 Restricted share units 152,750 651,883 720,550 Stock options 2,301,760 2,166,959 1,814,233 Warrants 1,755,330 2,089,084 2,305,272 Total dilutive shares 4,332,954 5,031,040 4,962,541 Revenue from Contracts with Customers In April 2015, the FASB issued ASU No. 2015-05, Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes 7,446 In January 2016, the FASB issued ASU No. 2016-01, Accounting for Equity Investments and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Discontinued Operations Effective November 12, 2015, the Company approved a plan to terminate its Phase 3 Aclerastide (DSC127) clinical program for diabetic foot ulcer healing. This action was based on futility determinations emanating out of the planned, pre-specified interim analyses of trial data conducted by the program’s independent Data Monitoring Committee (“DMC”). The decision to end the studies followed the recommendation by the DMC to stop the trials. Based on this recommendation, the Company initiated an orderly termination of all its existing pharmaceutical development activities, comprised of the diabetic foot ulcer healing program and two other programs utilizing the DSC127 compound for other therapeutic indications. As a result of these actions, the Company’s pharmaceutical development activities have been reported as discontinued operations in the Company’s Consolidated Financial Statements. Amounts previously reported in the Pharmaceutical Wound Care segment have been reclassified to conform to this presentation to allow for meaningful comparison of continuing operations. Included in the loss from discontinued operations in the consolidated statement of operations for the year ended December 31, 2015 are non-cash depreciation charges of $ 628 At December 31, 2015, the Company had $ 4,371,010

Restructuring and Other Charges

Restructuring and Other Charges	12 Months Ended
	Dec. 31, 2015
Restructuring Charges [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	Restructuring and Other Charges During the fourth quarter of 2015, the Company implemented a plan to reduce its cost structure in consideration of prospective market expectations for the business, coupled with the decision to move the business towards positive cash flow and profitability as soon as feasibly possible. The restructuring plan included the elimination of 39 952,534 Effective December 21, 2015, the Company’s Chairman of the Board, President and Chief Executive Officer (the “CEO”) departed from the Company. On February 26, 2016, the former CEO also resigned from the Company’s Board of Directors. While a national recruiting search for a permanent CEO is in process, the former lead director of the Company has assumed the role of Executive Chairman and Interim CEO. The Company incurred compensation and other benefit severance charges of $ 1,506,021 CEO Other Total Balance, January 1, 2015 $ - $ - $ - Charges during period 1,391,448 952,534 2,343,982 Payments during period (139,343) (125,602) (264,945) Balance, December 31, 2015 $ 1,252,105 $ 826,932 $ 2,079,037 Less current portion (665,182) (826,932) (1,492,114) Long term portion $ 586,923 $ - $ 586,923

Cash and Cash Equivalents and I

Cash and Cash Equivalents and Investments	12 Months Ended
	Dec. 31, 2015
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash, Cash Equivalents, and Short-term Investments [Text Block]	5. Cash and Cash Equivalents and Investments Cash and Cash Equivalents The Company considers cash and cash equivalents as amounts on hand, on deposit in financial institutions and highly liquid investments purchased with an original maturity of three months or less. The Company maintains cash and cash equivalents and money market mutual funds with various domestic and foreign financial institutions within the ordinary course of business, which at times may exceed jurisdictional insurance limits. Money market mutual funds consist of funds deposited into mutual funds investing in U.S. government and non-government obligations. Investments in debt securities Investments in debt securities includes certificates of deposit purchased with an original maturity greater than three months which are deposited in various U.S. financial institutions and are fully insured by the Federal Deposit Insurance Corporation. The Company intends to hold the certificates of deposit to maturity and accordingly these investments are carried at amortized cost. Investments in debt securities with maturities greater than one year from the balance sheet date are classified as a long-term asset. Investment in equity securities In 2013 and 2014, the Company purchased an aggregate 2,802,277 8,483,693 2,802,277 7.0 The investment in Comvita common stock is classified as an available-for-sale equity investment carried at fair value, with any unrealized gains and losses associated with the investment included in accumulated other comprehensive income and any dividends received recorded in other expense (income), net in the Consolidated Statement of Operations. The investment is classified as a long term asset because the Company intends to hold the investment longer than 12 months from the balance sheet date. As of December 31, 2015, the fair value of the Comvita common stock was $ 16,110,178 7,626,485 288,769 226,318 75,421 December 31, 2015 2014 Cash $ 10,784,522 $ 7,665,958 Cash equivalents 5,029,683 11,730,887 Cash and cash equivalents 15,814,205 19,396,845 Investments in debt securities 25,003,990 55,996,000 Investment in equity securities 16,110,178 8,422,790 Total investments 41,114,168 64,418,790 Total cash and cash equivalents and investments $ 56,928,373 $ 83,815,635 Fair Value Measurements, Using Total carrying Quoted prices Significant other Significant Cash and cash equivalents $ 15,814,205 $ 15,814,205 $ - $ - Investments in debt securities 25,003,990 25,003,990 - - Investment in equity securities 16,110,178 16,110,178 - - Total investments 41,114,168 41,114,168 - - Total $ 56,928,373 $ 56,928,373 $ - $ - The following table provides fair value information as of December 31, 2014: Fair Value Measurements, Using Total carrying Quoted prices Significant Significant Cash and cash equivalents $ 19,396,845 $ 19,396,845 $ - $ - Investments in debt securities 55,996,000 55,995,556 - - Investment in equity securities 8,422,790 8,422,790 - - Total investments 64,418,790 64,418,346 - - Total $ 83,815,635 $ 83,815,191 $ - $ - Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets. Level 2 inputs are quoted prices for similar assets in active markets or inputs that are observable for the asset, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management’s own assumptions used to measure assets at fair value. A financial asset’s classification is determined based on the lowest level input that is significant to the fair value measurement.

Accounts Receivable, net

Accounts Receivable, net	12 Months Ended
	Dec. 31, 2015
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	6. Accounts Receivable, net December 31, 2015 2014 Accounts receivable $ 8,850,116 $ 9,289,239 Less: Allowance for doubtful accounts (140,093) (136,995) Allowance for trade rebates (403,373) (257,815) Allowance for cash discounts and returns (161,061) (136,395) Accounts receivable, net $ 8,145,589 $ 8,758,034

Inventories

Inventories	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	7. Inventories December 31, 2015 2014 Finished goods $ 15,347,592 $ 8,386,356 Work in process 346,233 838,679 Packaging materials 1,152,993 1,343,927 Raw materials 3,843,888 2,711,978 Total inventory $ 20,690,706 $ 13,280,940

Equipment and Improvements, net

Equipment and Improvements, net	12 Months Ended
	Dec. 31, 2015
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	8. Equipment and Improvements, net Equipment and improvements, net include the following: December 31, 2015 2014 Machinery and equipment $ 7,872,773 $ 7,306,132 Furniture and fixtures 1,343,009 1,220,799 Leasehold improvements 2,547,967 2,769,371 Total equipment and improvements, gross 11,763,749 11,296,302 Less: accumulated depreciation (7,634,541) (7,681,863) Total equipment and improvements, net $ 4,129,208 $ 3,614,439

Identifiable Intangible Assets,

Identifiable Intangible Assets, net	12 Months Ended
	Dec. 31, 2015
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Intangible Assets Disclosure [Text Block]	Identifiable Intangible Assets, net Costs of identifiable intangible assets associated with previous acquisitions, as well as payments in connection with obtaining product license rights, are included as identifiable intangible assets. See Note 16 for product license rights agreements. December 31, Amortization 2015 2014 Product license rights $ 9,346,876 $ 9,346,876 6-10 years Developed technology and supply agreements 7,700,000 7,700,000 5-7 years Other 6,400,000 6,400,000 5-13 years Total identifiable intangible assets, gross 23,446,876 23,446,876 Less: accumulated amortization (13,615,631) (10,631,372) Total identifiable intangible assets, net $ 9,831,245 $ 12,815,504 2015 2014 2013 Cost of sales $ 2,209,259 $ 2,300,244 $ 2,009,472 Selling, general and administrative expenses 775,000 775,000 833,413 Total amortization expense $ 2,984,259 $ 3,075,244 $ 2,842,885 Amortization expense for product license rights and developed technology and supply agreements is included as a component of cost of sales and amortization of other identifiable intangible assets is included in selling, general and administrative expense in the Consolidated Statement of Operations. Product License Developed Other Total Amortization expense for the year ended December 31, 2015 $ 1,103,544 $ 1,105,715 $ 775,000 $ 2,984,259 Weighted Average Remaining Useful Life 4.2 3.3 2.0 3.3 Amortization expense for the year ended December 31, 2014 $ 1,194,529 $ 1,105,715 $ 775,000 $ 3,075,244 Amortization expense for the year ended December 31, 2013 $ 908,758 $ 1,100,714 $ 833,413 $ 2,842,885 Estimated amortization expense for years ending December 31, 2016 $ 1,104,213 $ 1,105,715 $ 626,250 $ 2,836,178 2017 1,104,213 1,105,715 281,667 2,491,595 2018 1,104,213 1,025,296 165,000 2,294,509 2019 1,017,534 382,084 165,000 1,564,618 2020 315,151 - 165,000 480,151 Thereafter 32,887 - 131,307 164,194 Total $ 4,678,211 $ 3,618,810 $ 1,534,224 $ 9,831,245

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	10. Accrued Expenses and Other Liabilities December 31, 2015 2014 Accrued compensation and related taxes $ 2,390,855 $ 2,845,250 Liabilities related to restructuring (Note 4) 2,079,037 - Accrued sales incentives and other fees 613,186 557,918 Accrued royalties 444,563 463,823 Accrued Canadian sales rebate, net (Note 16) 237,141 633,162 Other 1,940,936 1,544,058 Total accrued expenses and other liabilities $ 7,705,718 $ 6,044,211 Less current portion (6,691,340) (5,522,853) Long term liabilities $ 1,014,378 $ 521,358 At December 31, 2015 and 2014, the amount of the Canadian accrued sales rebate and other reserves exceeded the amount of the underlying trade receivables outstanding. The net credit balance in trade receivables was reclassified for financial reporting purposes to accrued expense to recognize it as a net liability.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Stockholders’ Equity Preferred Stock There are 18,598 32.00 There are 54,734 48.00 The certificates of designations, voting powers, preferences and rights of the Company’s series A and B convertible preferred stock provide, among other items, that the 1:1 preferred stock to common stock conversion ratio will be adjusted as of the closing date of any offering of common stock issued at less than the prevailing market price. In the event the market price exceeds the offering price of the common stock, the conversion ratios of any series of preferred stock then outstanding are to be adjusted in accordance with a prescribed formula. Subsequent to the issuances of the preferred stock, the Company has undertaken a number of common stock offerings that impact the above described adjustments to the preferred stock conversion ratios. As of December 31, 2015, current series A and B preferred stockholders holding 73,332 123,114 49,782 1,397 140,086 The 49,782 incremental shares associated with the conversion ratio adjustment will be recorded to common stock at par with the offset to additional paid in capital as all of the convertible preferred stock was issued prior to the November 16, 2000 effective date of certain provisions of Accounting Standards Codification 470 (formerly, Emerging Issues Task Force Issue No. 00-27 Application of Issue No. 98-5 to Certain Convertible Instruments) Common Stock During 2015, the Company issued 557,667 404,187 1,992,463 153,480 185,038 On June 6, 2014, the Company amended its Certificate of Incorporation to reflect an increase in the number of authorized shares of common stock. On May 20, 2014, stockholders of the Company approved the proposal to increase the number of authorized shares of common stock from 35,000,000 50,000,000 On January 29, 2014, the Company raised $ 80,616,032 5,633,968 7,500,000 11.50 During 2014, the Company issued 7,972,132 7,500,000 351,651 2,270,714 119,084 148,050 1,397 On May 29, 2013, the Company amended its Certificate of Incorporation to reflect an increase in the number of authorized shares of common stock from 25,000,000 During 2013, the Company issued 822,348 556,855 2,817,001 45,368 140,086 120,957 145,650 4,450 Stock Purchase Warrants Series Number of Warrants Exercise Price Expiration Date R 1,705,330 $ 9.90 June 22, 2016 S 50,000 $ 11.81 January 14, 2019 Total 1,755,330 During 2015, a total of 326,933 133,333 100,000 93,600 266,188 132,666 127,272 6,250 264,611 50,000 624,882 367,814 200,893 53,667 2,508 421,465 Equity Based Compensation Under the Derma Sciences, Inc. 2012 Equity Incentive Plan (the “EIP Plan”) the Company is authorized to issue 6,000,000 2,301,760 152,750 2,420,248 Stock Options The EIP Plan permits the granting of both incentive and nonqualified stock options to employees and nonqualified stock options to non-employee directors and consultants of the Company. The option exercise price may not be less than the fair market value of the stock on the date of the grant of the option. The duration of each option may not exceed 10 2015 2014 2013 Risk-free interest rate 1.63 % 1.79 % 1.22 % Volatility factor 46.1 % 63.2 % 69.9 % Dividend yield 0 % 0 % 0 % Expected option life (years) 5.81 5.79 6.14 The risk-free rate utilized represents the U.S. treasury yield curve rate for the expected option life at the time of grant. The volatility factor was calculated based on the Company’s historical stock price volatility equal to the expected life of the option at the grant date. The dividend yield is 0 Based on the Company’s historical experience of options that were forfeited before becoming fully vested, the Company has assumed an annualized forfeiture rate of 1.0 Options Weighted Weighted Outstanding – January 1, 2013 1,639,985 $ 6.38 Granted 421,480 $ 12.14 Forfeited (36,878) $ 10.99 Exercised (184,824) $ 5.50 Expired (25,530) $ 13.16 Outstanding – December 31, 2013 1,814,233 $ 7.67 6.4 years Granted 637,383 $ 12.98 Forfeited (116,765) $ 12.48 Exercised (145,053) $ 6.42 Expired (22,839) $ 10.70 Outstanding – December 31, 2014 2,166,959 $ 9.03 6.5 years Granted 609,090 $ 8.54 Forfeited (280,302) $ 9.96 Exercised (129,018) $ 4.19 Expired (64,969) $ 9.87 Outstanding – December 31, 2015 2,301,760 $ 9.04 6.5 years Exercisable at December 31, 2015 1,855,931 $ 8.65 Expected to vest at December 31, 2015 2,278,742 $ 9.07 During 2015, the Company granted 451,090 158,000 452,057 185,326 300,880 120,600 3.82 7.63 8.30 In 2015, 129,018 77,254 145,053 87,040 184,824 135,390 119,520 288,553 407,198 519,604 684,060 1,286,818 The aggregate intrinsic value of outstanding and exercisable stock options was $ 182,230 179,126 4.57 During the years ended December 31, 2015, 2014, and 2013 stock option compensation expense was recorded as follows: 2015 2014 2013 Cost of sales $ 168,800 $ 178,899 $ 95,726 Selling, general and administrative expenses 2,004,268 2,625,129 2,087,827 Discontinued operations 37,397 194,427 165,581 Total stock option compensation expense $ 2,210,465 $ 2,998,455 $ 2,349,134 As of December 31, 2015, there was $ 1,670,237 1.5 Restricted Share Units The Company has issued service, performance and market based restricted share units to employees and directors of the Company. Expense for restricted share awards is amortized on a straight-line basis over the awards’ vesting period. Number of Weighted Unvested – January 1, 2013 786,900 $ 8.78 Granted 79,300 $ 13.65 Vested (145,650) $ 10.18 Unvested – December 31, 2013 720,550 $ 9.03 Granted 101,100 $ 10.05 Vested (148,050) $ 11.86 Cancelled (21,717) $ 12.78 Unvested – December 31, 2014 651,883 $ 8.47 Granted 124,500 $ 7.39 Vested (185,038) $ 10.43 Cancelled (438,595) $ 7.30 Unvested – December 31, 2015 152,750 $ 8.59 In connection with the vesting of restricted share unit awards during the year ended December 31, 2015, 31,558 168,946 28,966 300,070 24,693 228,149 During 2015, 2014 and 2013, restricted share unit compensation expense was $ 2,388,101 2,593,239 2,634,340 As of December 31, 2015, the intrinsic value of the non-vested awards was $ 698,068 811,850 0.58 In December 2015, in consideration of prior service to the Company, the Company accelerated the vesting of all unvested stock options and restricted share units of the departing CEO. An additional $ 114,573 In May of 2015, in consideration of prior service to the Company, the Company granted a retiring director 15,000 36 70,670 In 2014, in consideration of prior service to the Company, the Company accelerated the vesting of stock options and the restricted share units scheduled to vest in 2014 of a retiring director and extended the date to exercise vested stock options to 24 48,536 In 2013, in consideration of prior service to the Company, a retiring director received 5,000 36 4,450 337,422 Shares Reserved for Future Issuance Convertible preferred shares (Series A – B) 73,332 Additional stock issuable related to conversion of 49,782 Common stock options outstanding 2,301,760 Common stock warrants outstanding 1,755,330 Restricted share units outstanding 152,750 Common stock equivalents available for grant 2,420,248 Total common stock shares reserved 6,753,202

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	12 Months Ended
	Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Comprehensive Income (Loss) Note [Text Block]	12. Accumulated Other Comprehensive Income Foreign Unrealized Total Balance at January 1, 2013 $ 1,588,888 $ - $ 1,588,888 Current period - other comprehensive loss (370,880) (137,860) (508,740) Balance at December 31, 2013 1,218,008 (137,860) 1,080,148 Current period - other comprehensive (loss) income (216,710) 48,125 (168,585) Balance at December 31, 2014 1,001,298 (89,735) 911,563 Current period - other comprehensive (loss) income (445,360) 4,806,705 4,361,345 Balance at December 31, 2015 $ 555,938 $ 4,716,970 $ 5,272,908

Operating Segments

Operating Segments	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	13. Operating Segments The Company operates in two segments: advanced wound care and traditional wound care products. They are managed separately as each segment requires different technology, marketing and sales strategies. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. Advanced and traditional wound care products are marketed globally to acute care, extended care, home health care, wound and burn care clinics and physician offices. The Company utilizes a broad network of well-established distributors to deploy the majority of its products to end users. A smaller portion of the Company’s sales are sold directly to care providers and through retail. The advanced and traditional wound care products are both manufactured internally and sourced from third party suppliers. The majority of marketing expenses are deployed in support of advanced wound care products with traditional wound care products requiring limited support. The Company utilizes direct sales representatives, distributor relationships and contractual relationships with buying groups and wound care service providers to sell its products. Direct sales representatives are used solely in support of advanced wound care sales in the U.S. and the U.K. and for both advanced and traditional wound care products in Canada. Each operating segment is managed at the segment contribution level consisting of gross profit minus direct expense consisting of distribution, marketing, sales, research and development and intangible amortization expenses. Expenses are allocated directly by segment to the extent possible. Expenses common to both operating segments are allocated consistently using activity based assumptions. The aggregation or allocation of indirect expenses by segment is not practical. Year Ended December 31, 2015 Advanced Traditional Other Total Net sales $ 41,782,144 $ 42,692,140 $ - $ 84,474,284 Gross profit 21,040,514 11,693,661 - 32,734,175 Direct expense (32,684,540) (5,156,199) - (37,840,739) Segment contribution $ (11,644,026) $ 6,537,462 - (5,106,564) Indirect expenses $ (15,260,099) (15,260,099) Net loss from continuing operations $ (20,366,663) Restructuring and $ 722,810 $ 105,075 $ 1,630,670 $ 2,458,555 Depreciation $ 512,862 $ 223,102 $ 189,633 $ 925,597 Amortization $ 2,699,259 $ 285,000 $ - $ 2,984,259 Capital expenditures $ 1,475,994 $ 75,441 $ 259,890 $ 1,811,325 As of December 31, 2015 Equipment and $ 2,649,208 $ 701,548 $ 778,452 $ 4,129,208 Identifiable intangible $ 9,379,938 $ 451,307 $ - $ 9,831,245 Goodwill $ 6,337,967 $ 7,119,726 $ - $ 13,457,693 Total assets $ 34,794,250 $ 23,956,132 $ 56,029,773 $ 114,780,155 Year Ended December 31, 2014 Advanced Traditional Other Total Net sales $ 38,110,851 $ 45,634,829 $ - $ 83,745,680 Gross profit 18,170,944 11,938,991 - 30,109,935 Direct expense (30,919,972) (5,193,516) - (36,113,488) Segment contribution $ (12,749,028) $ 6,745,475 - (6,003,553) Indirect expenses $ (14,841,062) (14,841,062) Net loss from continuing operations $ (20,844,615) Depreciation $ 464,686 $ 226,830 $ 176,098 $ 867,614 Amortization $ 2,789,763 $ 285,481 $ - $ 3,075,244 Capital expenditures $ 918,673 $ 198,374 $ 603,050 $ 1,720,097 As of December 31, 2014 Equipment and $ 2,274,254 $ 598,781 $ 725,619 $ 3,598,654 Identifiable intangible $ 12,079,197 $ 736,307 $ - $ 12,815,504 Goodwill $ 6,337,967 $ 7,119,726 $ - $ 13,457,693 Total assets $ 35,033,245 $ 20,475,555 $ 83,781,666 $ 139,290,466 Year Ended December 31, 2013 Advanced Traditional Other Total Net sales $ 33,928,535 $ 45,782,445 $ - $ 79,710,980 Gross profit 16,837,797 12,552,677 - 29,390,474 Direct expense (21,404,045) (5,059,141) - (26,463,186) Segment contribution $ (4,566,248) $ 7,493,536 - 2,927,288 Indirect expenses $ (15,456,784) (15,456,784) Net loss from continuing operations $ (12,529,496) Depreciation $ 477,118 $ 264,841 $ 136,192 $ 878,151 Amortization $ 2,557,805 $ 285,080 $ - $ 2,842,885 Capital Expenditures $ 437,169 $ 24,193 $ 234,414 $ 695,776 A geographical breakdown of the Company’s sales (based on customer location), gross profit, equipment and improvements, net, and intangible assets, net are as follows: United States Canada Other Total 2015 Net sales $ 65,613,639 $ 9,701,712 $ 9,158,933 $ 84,474,284 Gross profit $ 24,907,022 $ 4,263,083 $ 3,564,070 $ 32,734,175 Equipment and improvements, net $ 1,142,655 $ 2,859,316 $ 127,237 $ 4,129,208 Identifiable intangible assets, net $ 9,831,245 - - $ 9,831,245 Goodwill $ 13,457,693 - - $ 13,457,693 2014 Net sales $ 63,324,527 $ 11,859,900 $ 8,561,253 $ 83,745,680 Gross profit $ 25,415,410 $ 1,134,949 $ 3,559,576 $ 30,109,935 Equipment and improvements, net $ 1,204,152 $ 2,203,015 $ 207,272 $ 3,614,439 Identifiable intangible assets, net $ 12,815,504 - - $ 12,815,504 Goodwill $ 13,457,693 - - $ 13,457,693 2013 Net sales $ 61,234,755 $ 11,084,430 $ 7,391,795 $ 79,710,980 Gross profit $ 23,956,554 $ 2,371,054 $ 3,062,866 $ 29,390,474

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	14. Income Taxes Loss before income taxes from continuing operations for the year ended December 31, 2015, 2014 and 2013 consists of the following components: 2015 2014 2013 Domestic $ (23,246,881 ) $ (18,927,332 ) $ (11,710,997 ) Foreign 635,503 (2,068,331 ) (658,388 ) Loss before income taxes from continuing operations $ (22,611,378 ) $ (20,995,663 ) $ (12,369,385 ) The components of income tax (benefit) provision for the year ended December 31, 2015, 2014 and 2013 are as follows: 2015 2014 2013 Current: Federal $ - $ - $ - State - - 5,365 Foreign 481,241 (165,953 ) 22,590 Total current 481,241 (165,953 ) 27,955 Deferred: Federal (2,327,987 ) 124,316 149,108 State (493,065 ) (105,575 ) (34,143 ) Foreign 95,096 (3,836 ) 17,191 Total deferred (2,725,956 ) 14,905 132,156 Income tax (benefit) provision from continuing operations $ (2,244,715 ) $ (151,048 ) $ 160,111 In 2015, the Company recognized a $2,244,715 income tax benefit consisting of a $576,337 foreign income tax expense and a $2,821,052 U.S. deferred income tax benefit. The foreign income tax expense relates primarily to the tax expense recognized as a result of net income incurred by the Canadian operations, as well as taxes paid on the dividend from the Comvita investment. The U.S. deferred tax benefit related to a reduction in the Company’s U.S. valuation allowance to offset the tax impact of the unrealized gain on equity securities included in accumulated other comprehensive income of $2,880,683 and the deferred tax expense due to differences in financial reporting and tax treatment of goodwill of $166,000, partially offset by amortization for financial reporting but not tax purposes of acquired MedEfficiency identified intangible assets of $106,369. There was no tax effect as a result of discontinued operations. The reconciliation of income tax computed at the U.S. federal statutory tax rates to income tax (benefit) expense along with percentage of loss before income taxes from continuing operations for the year ended December 31, 2015, 2014 and 2013 is as follows: 2015 2014 2013 Tax benefit at federal statutory rate $ (7,687,869 ) 34.0 % $ (7,138,525 ) 34.0 % $ (4,205,591 ) 34.0 % State tax, net of federal benefit (674,428 ) 3.0 (557,058 ) 2.7 (354,144 ) 2.9 Foreign tax 30,389 (0.1 ) 199,505 (1.0 ) 74,612 (0.6 ) Nondeductible expenses 1,118,747 (4.9 ) 1,215,047 (5.8 ) 637,797 (5.2 ) Other 1,025,238 (4.5 ) (1,914,781 ) 9.1 (50,860 ) 0.4 Change in valuation allowance 3,943,208 (17.4 ) 8,044,764 (38.3 ) 4,058,297 (32.8 ) Income taxes $ (2,244,715 ) 9.9 % $ (151,048 ) 0.7 % $ 160,111 (1.3 %) Significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2015 2014 Deferred tax assets: Net operating loss carryforwards $ 41,857,037 $ 29,384,036 Equity based compensation 782,880 2,103,130 Allowance for sales deductions 261,558 198,625 Amortization of identified intangibles 2,092,885 2,047,495 Inventory adjustments 792,834 420,004 Tax credits 2,617,819 1,786,366 Other 1,217,224 720,203 Deferred tax assets 49,622,237 36,659,859 Deferred tax liabilities: Prepaid expenses (197,358 ) (185,803 ) Goodwill (1,513,377 ) (1,347,378 ) Depreciation (351,112 ) (348,135 ) Identified intangibles (1,651,571 ) (2,216,271 ) Unrealized gain on equity security (2,857,263 ) - Deferred tax liabilities (6,570,681 ) (4,097,587 ) Valuation allowance (44,856,072 ) (34,255,466 ) Net deferred tax liabilities $ (1,804,516 ) $ (1,693,194 ) The net deferred tax liability includes a U.S. deferred tax liability of $1,513,753 related to differences in the basis for financial reporting and tax purposes for goodwill and a net deferred tax liability of $290,763 related to the Canadian operations. At December 31, 2015, the Company has U.S. federal net operating loss carry forwards of approximately $112,461,000 that begin to expire in 2018. For U.S. state income tax purposes, the Company has net operating loss carry forwards in a number of jurisdictions in varying amounts that begin to expire in 2018. Federal and state net operating loss carryforwards include excess stock-based compensation benefit deductions of which, if recognized in the future, will be recorded as additional paid in capital in the Consolidated Balance Sheet. The Company also has $2,452,588 in research and development tax credit carry forwards and $165,231 in foreign tax credit carry forwards which begin to expire in 2031 and 2019, respectively. The Company has determined that the amount by which the U.S. federal net operating loss carryforwards can be utilized in any year is limited under the Internal Revenue Code Section 382 regarding changes in ownership of corporations. Due to uncertainties surrounding the Company’s ability to use its net operating loss carryforwards, foreign tax credit and realize the other net deferred tax assets based on historical operating results and ownership change limitations, a full valuation allowance has been provided as of December 31, 2015 and 2014 for the deferred tax assets for the U.S. and U.K.

Retirement Benefits

Retirement Benefits	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	15. Retirement Benefits The Company maintains a profit sharing 401(k) plan for eligible full-time U.S. employees. Participants may contribute a fixed percentage of their salary to the plan, subject to IRS limitations. The Company makes a matching contribution up to a maximum amount of each participant’s annual base salary earnings contributed to the plan. During 2015, 2014 and 2013, the Company matched 100 4 599,447 505,769 295,735 The Company’s Canadian subsidiary maintains a group retirement savings plan (Registered Retirement Savings Plan) for eligible full time Canadian employees. The Canadian subsidiary makes a matching contribution to the plan based on a percentage of each participant’s contributed annual gross earnings. Employee contribution limits to the group retirement savings plan are set by the Canada Customs and Revenue Agency. During 2015, 2014 and 2013, the Company matched 100 4 146,102 152,551 133,319

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	16. Commitments and Contingencies Operating Leases The Company has non-cancelable operating lease agreements for its facilities and equipment expiring in various years through 2021. Total lease expense under these lease agreements was $ 1,625,443 1,565,307 1,227,718 427,455 521,358 The leases generally provide for scheduled increases in future minimum annual lease payments over the life of the lease and for renewal options consistent with the terms of the existing lease. Minimum Future Rental Payments Year Ending December 31, Amount 2016 $ 1,627,939 2017 1,415,377 2018 937,226 2019 470,050 2020 276,901 Thereafter 53,038 Net minimum future rental payments $ 4,780,531 Comvita Licensing Agreement In February 2010, the Company entered into a new agreement with Comvita (the “Comvita Agreement”) under which the Company received perpetual and exclusive worldwide licensing rights for Manuka Honey based MEDIHONEY wound and skin care products for all markets outside of the consumer market. The Comvita Agreement supersedes the prior agreement, which was terminated as of the effective date. The Comvita Agreement also provides that Comvita will serve as the Company’s supplier for Manuka Honey and will not provide Manuka Honey to any other entities for use in the professional medical-surgical marketplace. The Comvita Agreement calls for graduated royalty payments based on sales and milestone payments of up to $ 20,000,000 2,000,000 Comvita is a stockholder of the Company and its former Chief Executive Officer serves on the Company’s Board of Directors. The Company purchased $ 4,014,969 2,203,992 2,266,964 1,336,559 1,357,040 1,240,818 506,795 625,947 8,483,693 125,000 Quick-Med Technologies, Inc. – License Agreement In July 2012, the Company entered into a new patent and technology license agreement (the “QMT Agreement”) with Quick-Med Technologies, Inc. (“QMT”) relating to QMT’s proprietary anti-microbial technology (the “Technology”) utilized in the Company’s BIOGUARD products. The QMT Agreement supersedes a prior agreement, which had been in effect since March 2007. Under the QMT Agreement, QMT granted to the Company an exclusive, royalty-bearing right and license to make, use and sell medical market (prescription) products incorporating the Technology worldwide, except for India (the “Territory”). If the Company does not achieve the first commercial sale of a product incorporating the Technology in Europe and in Asia and Central and South America by certain dates, or in the event that, for a given calendar year, the Company fails to meet a minimum net sales requirement under the QMT Agreement, QMT has the right, as its sole remedy within each geographic area affected, to either terminate the QMT Agreement or convert the exclusive license in that geographic area to a non-exclusive license. Unless otherwise terminated pursuant to the QMT Agreement, the term of the QMT Agreement continues, with respect to each country in the Territory, until the expiration of the patent rights in that country. In 2012, the Company paid QMT an upfront license fee of $ 1,300,000 3,500,000 178,546 178,476 202,377 In the event that QMT desires to sell the Technology, patent rights and improvements or QMT receives a bona fide offer from an unaffiliated third party to purchase the same during the term of the QMT Agreement, the Company has the right of first negotiation or right of first refusal, respectively, relating to any such sale. In 2015, the QMT Agreement with QMT was amended to grant to Derma exclusive rights within the Territory to make, use and sell traditional wound care products incorporating the Technology in the over-the-counter market. The Company is currently pursuing 510(k) approval from the FDA for over-the-counter use. BioDLogics, LLC License Agreement On January 14, 2014, the Company entered into a license, market development and commercialization agreement (the “Agreement”) with BioDLogics, LLC (“BioD”) relating to BioD’s human placental based products (the “Licensed Products”) and intellectual property related thereto. Under the Agreement, BioD granted to the Company an exclusive, perpetual, royalty-bearing license to use, offer for sale and sell, the Licensed Products in North America (the “BioD Territory”), including the rights to sublicense solely as provided in the Agreement, for a broad range of dermal applications (the “Field”). During the term of the Agreement, the Company will be responsible for the sale and marketing of the Licensed Products in the Field throughout the BioD Territory. As part of its commercialization efforts, the Company is required to fund clinical studies up to $ 2,000,000 The Company paid BioD an initial license fee of $ 1,250,000 100,000 25 11.81 75 Note 11 129,750 1,379,750 314,545 66,202 The Agreement also requires the Company to make milestone payments to BioD of up to $ 19,750,000 The Agreement may be terminated as follows: (i) upon mutual agreement of the parties; (ii) by BioD if the Company challenges certain BioD patents or trade secrets; (iii) by BioD if the Company fails to meet the annual minimum net sales requirement under the Agreement, unless the Company pays the difference between the amount of royalties that would have been due had the minimum annual net sales for such year been achieved and royalty payments made by the Company with respect to net sales during such year plus any milestone payments payable; or (iv) by either party in the event of a material breach or certain events of bankruptcy. The annual minimum net sales requirement commenced in 2015, and is $ 2,000,000 USC License Agreement In November 2007, the Company entered into a license agreement (the “License Agreement”) with the University of Southern California (“USC”) pursuant to which the Company acquired exclusive rights to a number of U.S. and foreign patents and non-exclusive rights to one patent, together with trade secrets and know-how, related to an angiotensin analog (the patents, trade secrets and know-how, collectively, the “Angiotensin Analog Technology”). The Angiotensin Analog Technology related to all dermal applications including applications for the treatment of chronic wounds such as diabetic ulcers, leg ulcers associated with venous insufficiency, pressure ulcers (bed sores), burns and surgical scars. Any license fees paid to or on behalf of USC were expensed as incurred. The compound employing the Angiotensin Analog Technology was classified as a “drug,” the sale of which was conditioned upon FDA approval. The process of obtaining FDA approval for the compound consisted of subjecting the compound to a series of pre-clinical and clinical studies, these latter known as Phase 1, Phase 2 and Phase 3 studies. In November of 2015, the Company terminated its Phase 3 clinical trials and determined not to conduct any further development work on the Angiotensin Analog Technology. In January 2016, the Company gave notice to USC terminating the license agreement. Canadian Distribution Agreement In May 2005, the Company entered into a distribution agreement with a Canadian company to serve as the exclusive distributor of its products in Canada. The agreement also appoints the distributor as the Company’s servicing agent to fulfill supply contracts held directly by the Company. The agreement was most recently amended in January 2011, extending it through April 2016. Both parties are presently negotiating renewal of the Agreement effective May 1, 2016. The Company recognizes revenue under the agreement when title and risk of loss pass to the distributor and collectability is reasonably assured, which is at the time product is shipped to the distributor. Payment terms from the distributor are 30 days. Either party has the right to terminate the agreement when an event of default (as defined) has occurred with respect to the other party. The distributor is entitled to continue to sell or otherwise dispose of all inventory owned by it from and after the date of contract expiration or termination. If termination of the agreement is not occasioned by breach by the distributor, the distributor will be entitled on notice to the Company to return saleable inventory (as defined) to the Company. At December 31, 2015, the distributor’s inventory of Company products was approximately $ 2,600,000 The distributor assumes responsibility for customer service, product delivery and maintenance and warehousing of sufficient inventory to meet agreed upon order fulfillment requirements. On an ongoing basis, the distributor places inventory replenishment orders with the Company at agreed upon prices, 120 days in advance of scheduled delivery. Unless amended, each order becomes non-cancelable 90 days in advance of scheduled delivery. With respect to sales made by the distributor, the Company pays the distributor an agreed upon distribution fee. The Company reimburses the distributor for the difference between the price paid by the distributor and the Company’s contract price with the end customer, upon submission by the distributor of an agreed upon rebate report. The distribution fee is recorded as a reduction of revenue under this agreement. New Cast Industry Co., Ltd. Supply Agreements On April 17, 2012, the Company entered into a supply agreement (the “North America Agreement”) with New Cast Industry Co. Ltd. (“NCIC”) relating to NCIC’s proprietary technology for the casting element within the TCC-EZ total contact casting system (the “NC Technology”). Under the North America Agreement, NCIC agreed to exclusively supply the Company with its product utilizing the NC Technology and granted the Company the exclusive right to sell products incorporating the NC Technology in North America. During the term of the North America Agreement, the Company is obligated to purchase an escalating minimum number of units of product each year. Product costs are negotiable in accordance with the agreement terms. Unless otherwise terminated pursuant to the terms of the North America Agreement, the term is for five years with automatic five year renewals. On March 27, 2013, the Company entered into a supply agreement (the “International Agreement”) with NCIC. Under the International Agreement, NCIC agreed to exclusively supply the Company with its product utilizing the NC Technology and granted the Company the exclusive right to sell products incorporating the NC Technology outside North America. If the Company does not achieve the first commercial sale of a product incorporating the NC Technology in Latin America, Europe, Middle East, Australia, Asia and India (the “NC Territory”) by certain dates, NCIC has the right, as its sole remedy, to convert the exclusive license in the NC Territory to a non-exclusive license. Unless otherwise terminated pursuant to the terms of the International Agreement, the term is for five years with automatic five year renewals. In consideration for the exclusive international rights set forth above, the Company paid NCIC $100,000. The cost of $ 100,000 1,000,000 Executive Employment Agreements The four executive officers of the Company are appointed by and serve at the discretion of the Board of Directors pursuant to two year employment agreements that are subject to renewal bi-annually as of April 1 st Contingencies On occasion, the Company is involved in claims and other legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position, results of operations, or liquidity.

Quarterly Consolidated Financia

Quarterly Consolidated Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	Quarterly Consolidated Financial Data (Unaudited) ($’s 000’s) First Quarter Second Quarter Third Quarter Fourth Quarter* Year** 2015: Net sales $ 19,499 $ 22,556 $ 22,169 $ 20,250 $ 84,474 Gross profit 7,535 8,371 8,436 8,392 32,734 Loss from continuing operations, (6,490) (5,026) (4,111) (4,739) (20,366) Loss from discontinued operations, (4,119) (4,260) (4,852) (4,510) (17,741) Net loss $ (10,609) $ (9,286) $ (8,963) $ (9,249) $ (38,107) Net loss per common share – basic Continuing operations $ (0.26) $ (0.19) $ (0.16) $ (0.18) $ (0.79) Discontinued operations (0.16) (0.17) (0.19) (0.18) (0.69) Total net loss per common share – basic and diluted $ (0.42) $ (0.36) $ (0.35) $ (0.36) $ (1.48) 2014: Net sales $ 19,787 $ 20,916 $ 20,169 $ 22,874 $ 83,746 Gross profit 6,912 7,845 6,359 8,994 30,110 Loss from continuing operations, (6,120) (4,359) (6,914) (3,452) (20,845) Loss from discontinued (4,150) (4,328) (4,334) (6,115) (18,927) Net loss $ (10,270) $ (8,687) $ (11,248) $ (9,567) $ (39,772) Net loss per common share – basic Continuing operations $ (0.28) $ (0.17) $ (0.28) $ (0.14) $ (0.85) Discontinued operations (0.18) (0.17) (0.17) (0.24) (0.77) Total net loss per common share – $ (0.46) $ (0.34) $ (0.45) $ (0.38) $ (1.62) * In the 4 th ** Quarterly amounts may not add total due to rounding.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Principles of Consolidation, Policy [Policy Text Block]	Principles of Consolidation
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
Foreign Currency Translation Policy [Policy Text Block]	2015 2014 2013 Cost of sales $ (697,105) $ 421,525 $ 57,894 Other expense (income), net 977,419 (13,537) (198,615) Total $ 280,314 $ 407,988 $ (140,721) Exchange rate fluctuations of foreign currency denominated assets and liabilities associated with inventory are included in cost of sales, while all other such fluctuations are included in other expense (income), net.
Concentration of Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk 250,000
Customer and Vendor Concentrations, Policy [Policy Text Block]	Customer and Vendor Concentrations – 11 14 14 38 32 29
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations Presentation of Financial Statements -Discontinued Operations
Inventory, Policy [Policy Text Block]	Inventories
Equipment and Improvements, Policy [Policy Text Block]	Equipment and Improvements 10
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments
Identifiable Intangible Assets , Policy [Policy Text Block]	Identifiable Intangible Assets 13
Long Lived Assets, Policy [Policy Text Block]	Long Lived Assets
Goodwill, Policy [Policy Text Block]	Goodwill
Stock-Based Compensation, Policy [Policy Text Block]	Stock-Based Compensation
Income Tax, Policy [Policy Text Block]	Income Taxes The Company measures and recognizes the tax implications of positions taken or expected to be taken in its tax returns on an ongoing basis. In 2015, 2014 and 2013, the Company had no unrecognized tax benefits or liabilities, and no adjustment to its financial position, results of operations or cash flows were required. The Company records interest and penalties related to tax matters within other expense (income), net on the accompanying Consolidated Statements of Operations. These amounts are not material to the consolidated financial statements for the periods presented. The Company’s U.S. tax returns are subject to examination by federal and state taxing authorities. Tax years prior to 2012 are no longer subject to federal examination. However, the Company's federal net operating losses for tax years 2001 through 2011 will remain subject to examination until the losses are utilized or expire. State tax years 2011 to 2015 remain open to examination by the various state jurisdictions in which the Company is subject to tax. Tax years prior to 2006, as well as the 2007 tax year, are no longer subject to examination in Canada. The U.K. tax returns prior to 2013 are no longer subject to examination.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
Advertising and Promotion Costs, Policy [Policy Text Block]	Advertising and Promotion Costs 3,990,571 3,531,561 3,082,221
Royalties, Policy [Policy Text Block]	Royalties – 2,185,161 1,853,187 1,741,742
Net Loss Per Share, Policy [Policy Text Block]	Year Ended December 31, 2015 2014 2013 Excluded dilutive shares: Convertible preferred stock 73,332 73,332 73,332 Additional stock issuable related 49,782 49,782 49,154 Restricted share units 152,750 651,883 720,550 Stock options 2,301,760 2,166,959 1,814,233 Warrants 1,755,330 2,089,084 2,305,272 Total dilutive shares 4,332,954 5,031,040 4,962,541
Recently Issued Accounting Pronouncements, Policy [Policy Text Block]	Revenue from Contracts with Customers In April 2015, the FASB issued ASU No. 2015-05, Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes 7,446 In January 2016, the FASB issued ASU No. 2016-01, Accounting for Equity Investments and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule Of Foreign Currency Income [Table Text Block]	2015 2014 2013 Cost of sales $ (697,105) $ 421,525 $ 57,894 Other expense (income), net 977,419 (13,537) (198,615) Total $ 280,314 $ 407,988 $ (140,721)
Potentially Dilutive Shares Excluded as Result of Effects Being Anti-dilutive [Table Text Block]	Potentially dilutive shares excluded as a result of the effects being anti-dilutive are as follows: Year Ended December 31, 2015 2014 2013 Excluded dilutive shares: Convertible preferred stock 73,332 73,332 73,332 Additional stock issuable related 49,782 49,782 49,154 Restricted share units 152,750 651,883 720,550 Stock options 2,301,760 2,166,959 1,814,233 Warrants 1,755,330 2,089,084 2,305,272 Total dilutive shares 4,332,954 5,031,040 4,962,541

Restructuring and Other Charg29

Restructuring and Other Charges (Tables)	12 Months Ended
	Dec. 31, 2015
Restructuring Charges [Abstract]
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	Liabilities related to restructuring and other charges during 2015 are as follows: CEO Other Total Balance, January 1, 2015 $ - $ - $ - Charges during period 1,391,448 952,534 2,343,982 Payments during period (139,343) (125,602) (264,945) Balance, December 31, 2015 $ 1,252,105 $ 826,932 $ 2,079,037 Less current portion (665,182) (826,932) (1,492,114) Long term portion $ 586,923 $ - $ 586,923

Cash and Cash Equivalents and30

Cash and Cash Equivalents and Investments (Tables)	12 Months Ended
	Dec. 31, 2015
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Schedule Of Cash And Cash Equivalents And Investments [Table Text Block]	Cash and cash equivalents and investments at December 31, 2015 and 2014 consisted of the following: December 31, 2015 2014 Cash $ 10,784,522 $ 7,665,958 Cash equivalents 5,029,683 11,730,887 Cash and cash equivalents 15,814,205 19,396,845 Investments in debt securities 25,003,990 55,996,000 Investment in equity securities 16,110,178 8,422,790 Total investments 41,114,168 64,418,790 Total cash and cash equivalents and investments $ 56,928,373 $ 83,815,635
Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]	The following table provides fair value information as of December 31, 2015: Fair Value Measurements, Using Total carrying Quoted prices Significant other Significant Cash and cash equivalents $ 15,814,205 $ 15,814,205 $ - $ - Investments in debt securities 25,003,990 25,003,990 - - Investment in equity securities 16,110,178 16,110,178 - - Total investments 41,114,168 41,114,168 - - Total $ 56,928,373 $ 56,928,373 $ - $ - The following table provides fair value information as of December 31, 2014: Fair Value Measurements, Using Total carrying Quoted prices Significant Significant Cash and cash equivalents $ 19,396,845 $ 19,396,845 $ - $ - Investments in debt securities 55,996,000 55,995,556 - - Investment in equity securities 8,422,790 8,422,790 - - Total investments 64,418,790 64,418,346 - - Total $ 83,815,635 $ 83,815,191 $ - $ -

Accounts Receivable, net (Table

Accounts Receivable, net (Tables)	12 Months Ended
	Dec. 31, 2015
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	December 31, 2015 2014 Accounts receivable $ 8,850,116 $ 9,289,239 Less: Allowance for doubtful accounts (140,093) (136,995) Allowance for trade rebates (403,373) (257,815) Allowance for cash discounts and returns (161,061) (136,395) Accounts receivable, net $ 8,145,589 $ 8,758,034

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories include the following: December 31, 2015 2014 Finished goods $ 15,347,592 $ 8,386,356 Work in process 346,233 838,679 Packaging materials 1,152,993 1,343,927 Raw materials 3,843,888 2,711,978 Total inventory $ 20,690,706 $ 13,280,940

Equipment and Improvements, n33

Equipment and Improvements, net (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Equipment and improvements, net include the following: December 31, 2015 2014 Machinery and equipment $ 7,872,773 $ 7,306,132 Furniture and fixtures 1,343,009 1,220,799 Leasehold improvements 2,547,967 2,769,371 Total equipment and improvements, gross 11,763,749 11,296,302 Less: accumulated depreciation (7,634,541) (7,681,863) Total equipment and improvements, net $ 4,129,208 $ 3,614,439

Identifiable Intangible Asset34

Identifiable Intangible Assets, net (Tables)	12 Months Ended
	Dec. 31, 2015
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Identifiable intangible assets, net include the following: December 31, Amortization 2015 2014 Product license rights $ 9,346,876 $ 9,346,876 6-10 years Developed technology and supply agreements 7,700,000 7,700,000 5-7 years Other 6,400,000 6,400,000 5-13 years Total identifiable intangible assets, gross 23,446,876 23,446,876 Less: accumulated amortization (13,615,631) (10,631,372) Total identifiable intangible assets, net $ 9,831,245 $ 12,815,504
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	During the years ended December 31, 2015, 2014 and 2013, amortization expense was recorded as follows: 2015 2014 2013 Cost of sales $ 2,209,259 $ 2,300,244 $ 2,009,472 Selling, general and administrative expenses 775,000 775,000 833,413 Total amortization expense $ 2,984,259 $ 3,075,244 $ 2,842,885
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Amortization expense for 2015, 2014 and 2013 and estimated amounts thereafter by year are as follows: Product License Developed Other Total Amortization expense for the year ended December 31, 2015 $ 1,103,544 $ 1,105,715 $ 775,000 $ 2,984,259 Weighted Average Remaining Useful Life 4.2 3.3 2.0 3.3 Amortization expense for the year ended December 31, 2014 $ 1,194,529 $ 1,105,715 $ 775,000 $ 3,075,244 Amortization expense for the year ended December 31, 2013 $ 908,758 $ 1,100,714 $ 833,413 $ 2,842,885 Estimated amortization expense for years ending December 31, 2016 $ 1,104,213 $ 1,105,715 $ 626,250 $ 2,836,178 2017 1,104,213 1,105,715 281,667 2,491,595 2018 1,104,213 1,025,296 165,000 2,294,509 2019 1,017,534 382,084 165,000 1,564,618 2020 315,151 - 165,000 480,151 Thereafter 32,887 - 131,307 164,194 Total $ 4,678,211 $ 3,618,810 $ 1,534,224 $ 9,831,245

Accrued Expenses and Other Li35

Accrued Expenses and Other Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Current Liabilities [Table Text Block]	December 31, 2015 2014 Accrued compensation and related taxes $ 2,390,855 $ 2,845,250 Liabilities related to restructuring (Note 4) 2,079,037 - Accrued sales incentives and other fees 613,186 557,918 Accrued royalties 444,563 463,823 Accrued Canadian sales rebate, net (Note 16) 237,141 633,162 Other 1,940,936 1,544,058 Total accrued expenses and other liabilities $ 7,705,718 $ 6,044,211 Less current portion (6,691,340) (5,522,853) Long term liabilities $ 1,014,378 $ 521,358

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	At December 31, 2015, the Company had warrants outstanding to purchase shares of the Company’s common stock consisting of the following: Series Number of Warrants Exercise Price Expiration Date R 1,705,330 $ 9.90 June 22, 2016 S 50,000 $ 11.81 January 14, 2019 Total 1,755,330
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	For the years ended December 31, 2015, 2014 and 2013, the fair value of each option award was estimated at the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions for the years ended December 31, 2015, 2014 and 2013 were as follows: 2015 2014 2013 Risk-free interest rate 1.63 % 1.79 % 1.22 % Volatility factor 46.1 % 63.2 % 69.9 % Dividend yield 0 % 0 % 0 % Expected option life (years) 5.81 5.79 6.14
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the Company’s stock option activity and related information for the years ended December 31, 2015, 2014 and 2013 follows: Options Weighted Weighted Outstanding – January 1, 2013 1,639,985 $ 6.38 Granted 421,480 $ 12.14 Forfeited (36,878) $ 10.99 Exercised (184,824) $ 5.50 Expired (25,530) $ 13.16 Outstanding – December 31, 2013 1,814,233 $ 7.67 6.4 years Granted 637,383 $ 12.98 Forfeited (116,765) $ 12.48 Exercised (145,053) $ 6.42 Expired (22,839) $ 10.70 Outstanding – December 31, 2014 2,166,959 $ 9.03 6.5 years Granted 609,090 $ 8.54 Forfeited (280,302) $ 9.96 Exercised (129,018) $ 4.19 Expired (64,969) $ 9.87 Outstanding – December 31, 2015 2,301,760 $ 9.04 6.5 years Exercisable at December 31, 2015 1,855,931 $ 8.65 Expected to vest at December 31, 2015 2,278,742 $ 9.07
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	During the years ended December 31, 2015, 2014, and 2013 stock option compensation expense was recorded as follows: 2015 2014 2013 Cost of sales $ 168,800 $ 178,899 $ 95,726 Selling, general and administrative expenses 2,004,268 2,625,129 2,087,827 Discontinued operations 37,397 194,427 165,581 Total stock option compensation expense $ 2,210,465 $ 2,998,455 $ 2,349,134
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	The following table summarizes the restricted share unit activity for the years ended December 31, 2015, 2014 and 2013: Number of Weighted Unvested – January 1, 2013 786,900 $ 8.78 Granted 79,300 $ 13.65 Vested (145,650) $ 10.18 Unvested – December 31, 2013 720,550 $ 9.03 Granted 101,100 $ 10.05 Vested (148,050) $ 11.86 Cancelled (21,717) $ 12.78 Unvested – December 31, 2014 651,883 $ 8.47 Granted 124,500 $ 7.39 Vested (185,038) $ 10.43 Cancelled (438,595) $ 7.30 Unvested – December 31, 2015 152,750 $ 8.59
Schedule Of Common Stock Shares Reserved For Issuance And Shares Available For Grant [Table Text Block]	At December 31, 2015, the Company had reserved the following shares of common stock for future issuance: Convertible preferred shares (Series A – B) 73,332 Additional stock issuable related to conversion of 49,782 Common stock options outstanding 2,301,760 Common stock warrants outstanding 1,755,330 Restricted share units outstanding 152,750 Common stock equivalents available for grant 2,420,248 Total common stock shares reserved 6,753,202

Accumulated Other Comprehensi37

Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The Company’s accumulated other comprehensive income as of December 31, 2015, 2014 and 2013 was as follows: Foreign Unrealized Total Balance at January 1, 2013 $ 1,588,888 $ - $ 1,588,888 Current period - other comprehensive loss (370,880) (137,860) (508,740) Balance at December 31, 2013 1,218,008 (137,860) 1,080,148 Current period - other comprehensive (loss) income (216,710) 48,125 (168,585) Balance at December 31, 2014 1,001,298 (89,735) 911,563 Current period - other comprehensive (loss) income (445,360) 4,806,705 4,361,345 Balance at December 31, 2015 $ 555,938 $ 4,716,970 $ 5,272,908

Operating Segments (Tables)

Operating Segments (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Year Ended December 31, 2015 Advanced Traditional Other Total Net sales $ 41,782,144 $ 42,692,140 $ - $ 84,474,284 Gross profit 21,040,514 11,693,661 - 32,734,175 Direct expense (32,684,540) (5,156,199) - (37,840,739) Segment contribution $ (11,644,026) $ 6,537,462 - (5,106,564) Indirect expenses $ (15,260,099) (15,260,099) Net loss from continuing operations $ (20,366,663) Restructuring and $ 722,810 $ 105,075 $ 1,630,670 $ 2,458,555 Depreciation $ 512,862 $ 223,102 $ 189,633 $ 925,597 Amortization $ 2,699,259 $ 285,000 $ - $ 2,984,259 Capital expenditures $ 1,475,994 $ 75,441 $ 259,890 $ 1,811,325 As of December 31, 2015 Equipment and $ 2,649,208 $ 701,548 $ 778,452 $ 4,129,208 Identifiable intangible $ 9,379,938 $ 451,307 $ - $ 9,831,245 Goodwill $ 6,337,967 $ 7,119,726 $ - $ 13,457,693 Total assets $ 34,794,250 $ 23,956,132 $ 56,029,773 $ 114,780,155 Year Ended December 31, 2014 Advanced Traditional Other Total Net sales $ 38,110,851 $ 45,634,829 $ - $ 83,745,680 Gross profit 18,170,944 11,938,991 - 30,109,935 Direct expense (30,919,972) (5,193,516) - (36,113,488) Segment contribution $ (12,749,028) $ 6,745,475 - (6,003,553) Indirect expenses $ (14,841,062) (14,841,062) Net loss from continuing operations $ (20,844,615) Depreciation $ 464,686 $ 226,830 $ 176,098 $ 867,614 Amortization $ 2,789,763 $ 285,481 $ - $ 3,075,244 Capital expenditures $ 918,673 $ 198,374 $ 603,050 $ 1,720,097 As of December 31, 2014 Equipment and $ 2,274,254 $ 598,781 $ 725,619 $ 3,598,654 Identifiable intangible $ 12,079,197 $ 736,307 $ - $ 12,815,504 Goodwill $ 6,337,967 $ 7,119,726 $ - $ 13,457,693 Total assets $ 35,033,245 $ 20,475,555 $ 83,781,666 $ 139,290,466 Year Ended December 31, 2013 Advanced Traditional Other Total Net sales $ 33,928,535 $ 45,782,445 $ - $ 79,710,980 Gross profit 16,837,797 12,552,677 - 29,390,474 Direct expense (21,404,045) (5,059,141) - (26,463,186) Segment contribution $ (4,566,248) $ 7,493,536 - 2,927,288 Indirect expenses $ (15,456,784) (15,456,784) Net loss from continuing operations $ (12,529,496) Depreciation $ 477,118 $ 264,841 $ 136,192 $ 878,151 Amortization $ 2,557,805 $ 285,080 $ - $ 2,842,885 Capital Expenditures $ 437,169 $ 24,193 $ 234,414 $ 695,776
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	A geographical breakdown of the Company’s sales (based on customer location), gross profit, equipment and improvements, net, and intangible assets, net are as follows: United States Canada Other Total 2015 Net sales $ 65,613,639 $ 9,701,712 $ 9,158,933 $ 84,474,284 Gross profit $ 24,907,022 $ 4,263,083 $ 3,564,070 $ 32,734,175 Equipment and improvements, net $ 1,142,655 $ 2,859,316 $ 127,237 $ 4,129,208 Identifiable intangible assets, net $ 9,831,245 - - $ 9,831,245 Goodwill $ 13,457,693 - - $ 13,457,693 2014 Net sales $ 63,324,527 $ 11,859,900 $ 8,561,253 $ 83,745,680 Gross profit $ 25,415,410 $ 1,134,949 $ 3,559,576 $ 30,109,935 Equipment and improvements, net $ 1,204,152 $ 2,203,015 $ 207,272 $ 3,614,439 Identifiable intangible assets, net $ 12,815,504 - - $ 12,815,504 Goodwill $ 13,457,693 - - $ 13,457,693 2013 Net sales $ 61,234,755 $ 11,084,430 $ 7,391,795 $ 79,710,980 Gross profit $ 23,956,554 $ 2,371,054 $ 3,062,866 $ 29,390,474

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Loss before income taxes from continuing operations for the year ended December 31, 2015, 2014 and 2013 consists of the following components: 2015 2014 2013 Domestic $ (23,246,881) $ (18,927,332) $ (11,710,997) Foreign 635,503 (2,068,331) (658,388) Loss before income taxes from continuing operations $ (22,611,378) $ (20,995,663) $ (12,369,385)
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of income tax (benefit) provision for the year ended December 31, 2015, 2014 and 2013 are as follows: 2015 2014 2013 Current: Federal $ - $ - $ - State - - 5,365 Foreign 481,241 (165,953) 22,590 Total current 481,241 (165,953) 27,955 Deferred: Federal (2,327,987) 124,316 149,108 State (493,065) (105,575) (34,143) Foreign 95,096 (3,836) 17,191 Total deferred (2,725,956) 14,905 132,156 Income tax (benefit) provision from $ (2,244,715) $ (151,048) $ 160,111
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The reconciliation of income tax computed at the U.S. federal statutory tax rates to income tax (benefit) expense along with percentage of loss before income taxes from continuing operations for the year ended December 31, 2015, 2014 and 2013 is as follows: 2015 2014 2013 Tax benefit at federal statutory rate $ (7,687,869) 34.0 % $ (7,138,525) 34.0 % $ (4,205,591) 34.0 % State tax, net of federal benefit (674,428) 3.0 (557,058) 2.7 (354,144) 2.9 Foreign tax 30,389 (0.1) 199,505 (1.0) 74,612 (0.6) Nondeductible expenses 1,118,747 (4.9) 1,215,047 (5.8) 637,797 (5.2) Other 1,025,238 (4.5) (1,914,781) 9.1 (50,860) 0.4 Change in valuation allowance 3,943,208 (17.4) 8,044,764 (38.3) 4,058,297 (32.8) Income taxes $ (2,244,715) 9.9 % $ (151,048) 0.7 % $ 160,111 (1.3) %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2015 2014 Deferred tax assets: Net operating loss carryforwards $ 41,857,037 $ 29,384,036 Equity based compensation 782,880 2,103,130 Allowance for sales deductions 261,558 198,625 Amortization of identified intangibles 2,092,885 2,047,495 Inventory adjustments 792,834 420,004 Tax credits 2,617,819 1,786,366 Other 1,217,224 720,203 Deferred tax assets 49,622,237 36,659,859 Deferred tax liabilities: Prepaid expenses (197,358 ) (185,803 ) Goodwill (1,513,377 ) (1,347,378 ) Depreciation (351,112 ) (348,135 ) Identified intangibles (1,651,571 ) (2,216,271 ) Unrealized gain on equity security (2,857,263 ) - Deferred tax liabilities (6,570,681 ) (4,097,587 ) Valuation allowance (44,856,072 ) (34,255,466 ) Net deferred tax liabilities $ (1,804,516 ) $ (1,693,194 )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Minimum Future Rental Payments Year Ending December 31, Amount 2016 $ 1,627,939 2017 1,415,377 2018 937,226 2019 470,050 2020 276,901 Thereafter 53,038 Net minimum future rental payments $ 4,780,531

Quarterly Consolidated Financ41

Quarterly Consolidated Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information [Table Text Block]	($’s 000’s) First Quarter Second Quarter Third Quarter Fourth Quarter* Year** 2015: Net sales $ 19,499 $ 22,556 $ 22,169 $ 20,250 $ 84,474 Gross profit 7,535 8,371 8,436 8,392 32,734 Loss from continuing operations, (6,490) (5,026) (4,111) (4,739) (20,366) Loss from discontinued operations, (4,119) (4,260) (4,852) (4,510) (17,741) Net loss $ (10,609) $ (9,286) $ (8,963) $ (9,249) $ (38,107) Net loss per common share – basic Continuing operations $ (0.26) $ (0.19) $ (0.16) $ (0.18) $ (0.79) Discontinued operations (0.16) (0.17) (0.19) (0.18) (0.69) Total net loss per common share – basic and diluted $ (0.42) $ (0.36) $ (0.35) $ (0.36) $ (1.48) 2014: Net sales $ 19,787 $ 20,916 $ 20,169 $ 22,874 $ 83,746 Gross profit 6,912 7,845 6,359 8,994 30,110 Loss from continuing operations, (6,120) (4,359) (6,914) (3,452) (20,845) Loss from discontinued (4,150) (4,328) (4,334) (6,115) (18,927) Net loss $ (10,270) $ (8,687) $ (11,248) $ (9,567) $ (39,772) Net loss per common share – basic Continuing operations $ (0.28) $ (0.17) $ (0.28) $ (0.14) $ (0.85) Discontinued operations (0.18) (0.17) (0.17) (0.24) (0.77) Total net loss per common share – $ (0.46) $ (0.34) $ (0.45) $ (0.38) $ (1.62) * In the 4 th ** Quarterly amounts may not add total due to rounding.

Summary of Significant Accoun42

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Foreign Currency Transaction Gain (Loss), Realized	$ 280,314	$ 407,988	$ (140,721)
Other expense (income), net [Member]
Foreign Currency Transaction Gain (Loss), Realized	977,419	(13,537)	(198,615)
Cost of Sales [Member]
Foreign Currency Transaction Gain (Loss), Realized	$ (697,105)	$ 421,525	$ 57,894

Summary of Significant Accoun43

Summary of Significant Accounting Policies (Details 1) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,332,954	5,031,040	4,962,541
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	73,332	73,332	73,332
Additional stock issuable related to conversion of preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	49,782	49,782	49,154
Restricted share units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	152,750	651,883	720,550
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,301,760	2,166,959	1,814,233
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,755,330	2,089,084	2,305,272

Summary of Significant Accoun44

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Nov. 30, 2015
Cash, FDIC Insured Amount	$ 250,000
Advertising Expense	3,990,571	$ 3,531,561	$ 3,082,221
Royalty Expense	$ 2,185,161	$ 1,853,187	$ 1,741,742
Deferred Tax Assets, Net, Total				$ 7,446
Sales Revenue, Net [Member] | Supplier [Member]
Concentration Risk, Percentage	38.00%	32.00%	29.00%
Sales Revenue, Net [Member] | Customer [Member]
Concentration Risk, Percentage	11.00%	14.00%	14.00%
Maximum [Member]
Property, Plant and Equipment, Useful Life	10 years
Finite-Lived Intangible Asset, Useful Life	13 years
Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Finite-Lived Intangible Asset, Useful Life	5 years

Discontinued Operations (Detail

Discontinued Operations (Details Textual)	12 Months Ended
	Dec. 31, 2015USD ($)
Severance Costs	$ 4,371,010
Depreciation and Amortization, Discontinued Operations	$ 628

Restructuring and Other Charg46

Restructuring and Other Charges (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Beginning, Balance	$ 0
Charges during period	2,343,982
Payments during period	(264,945)
Ending, Balance	2,079,037
Less current portion	(1,492,114)
Long term portion	586,923
Chief Executive Officer [Member]
Beginning, Balance	0
Charges during period	1,391,448
Payments during period	(139,343)
Ending, Balance	1,252,105
Less current portion	(665,182)
Long term portion	586,923
Other Employees [Member]
Beginning, Balance	0
Charges during period	952,534
Payments during period	(125,602)
Ending, Balance	826,932
Less current portion	(826,932)
Long term portion	$ 0

Restructuring and Other Charg47

Restructuring and Other Charges (Details Textual)	3 Months Ended	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2015USD ($)
Restructuring and Related Cost, Number of Positions Eliminated	39
Severance Costs		$ 4,371,010
Chief Executive Officer [Member]
Severance Costs		1,506,021
Allocated Share-based Compensation Expense		$ 114,573
Other Non-employees [Member]
Severance Costs	$ 952,534

Cash and Cash Equivalents and48

Cash and Cash Equivalents and Investments (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012
Cash	$ 10,784,522	$ 7,665,958
Cash equivalents	5,029,683	11,730,887
Cash and cash equivalents	15,814,205	19,396,845	[1]	$ 6,501,586	$ 41,616,657
Investments in debt securities	25,003,990	55,996,000
Investment in equity securities	16,110,178	8,422,790
Total investments	41,114,168	64,418,790
Total cash and cash equivalents and investments	$ 56,928,373	$ 83,815,635
[1]	Reclassified for discontinued operations. See note 3.

Cash and Cash Equivalents and49

Cash and Cash Equivalents and Investments (Details 1) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Cash and cash equivalents	$ 15,814,205	$ 19,396,845
Investments	41,114,168	64,418,790
Total	56,928,373	83,815,635
Debt Securities [Member]
Investments	25,003,990	55,996,000
Equity Securities [Member]
Investments	16,110,178	8,422,790
Quoted prices in active markets (Level 1) [Member]
Cash and cash equivalents	15,814,205	19,396,845
Investments	41,114,168	64,418,346
Total	56,928,373	83,815,191
Quoted prices in active markets (Level 1) [Member] | Debt Securities [Member]
Investments	25,003,990	55,995,556
Quoted prices in active markets (Level 1) [Member] | Equity Securities [Member]
Investments	16,110,178	8,422,790
Significant other observable inputs (Level 2) [Member]
Cash and cash equivalents	0	0
Investments	0	0
Total	0	0
Significant other observable inputs (Level 2) [Member] | Debt Securities [Member]
Investments	0	0
Significant other observable inputs (Level 2) [Member] | Equity Securities [Member]
Investments	0	0
Significant unobservable inputs (Level 3) [Member]
Cash and cash equivalents	0	0
Investments	0	0
Total	0	0
Significant unobservable inputs (Level 3) [Member] | Debt Securities [Member]
Investments	0	0
Significant unobservable inputs (Level 3) [Member] | Equity Securities [Member]
Investments	$ 0	$ 0

Cash and Cash Equivalents and50

Cash and Cash Equivalents and Investments (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equity securities	2,802,277	2,802,277	2,802,277
Ownership percentage	7.00%
Available-for-sale Equity Securities, Amortized Cost Basis		$ 8,483,693	$ 8,483,693
Available-for-sale Securities, Equity Securities	$ 16,110,178	8,422,790
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	7,626,485
Investment Income, Dividend	$ 288,769	$ 226,318	$ 75,421

Accounts Receivable, net (Detai

Accounts Receivable, net (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accounts receivable	$ 8,850,116	$ 9,289,239
Less: Allowance for doubtful accounts	(140,093)	(136,995)
Allowance for trade rebates	(403,373)	(257,815)
Allowance for cash discounts and returns	(161,061)	(136,395)
Accounts receivable, net	$ 8,145,589	$ 8,758,034	[1]
[1]	Reclassified for discontinued operations. See note 3.

Inventories (Details)

Inventories (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Finished goods	$ 15,347,592	$ 8,386,356
Work in process	346,233	838,679
Packaging materials	1,152,993	1,343,927
Raw materials	3,843,888	2,711,978
Total inventory	$ 20,690,706	$ 13,280,940	[1]
[1]	Reclassified for discontinued operations. See note 3.

Equipment and Improvements, n53

Equipment and Improvements, net (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment, Gross, Total	$ 11,763,749	$ 11,296,302
Less: accumulated depreciation	(7,634,541)	(7,681,863)
Total equipment and improvements, net	4,129,208	3,614,439	[1]
Machinery and Equipment [Member]
Property, Plant and Equipment, Gross, Total	7,872,773	7,306,132
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross, Total	1,343,009	1,220,799
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross, Total	$ 2,547,967	$ 2,769,371
[1]	Reclassified for discontinued operations. See note 3.

Identifiable Intangible Asset54

Identifiable Intangible Assets, net (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets, Gross	$ 23,446,876	$ 23,446,876
Less accumulated amortization	(13,615,631)	(10,631,372)
Total	$ 9,831,245	12,815,504
Maximum [Member]
Amortization Period	13 years
Minimum [Member]
Amortization Period	5 years
Product license rights [Member]
Finite-Lived Intangible Assets, Gross	$ 9,346,876	9,346,876
Total	$ 4,678,211
Product license rights [Member] | Maximum [Member]
Amortization Period	10 years
Product license rights [Member] | Minimum [Member]
Amortization Period	6 years
Developed technology and supply agreements [Member]
Finite-Lived Intangible Assets, Gross	$ 7,700,000	7,700,000
Developed technology and supply agreements [Member] | Maximum [Member]
Amortization Period	7 years
Developed technology and supply agreements [Member] | Minimum [Member]
Amortization Period	5 years
Other [Member]
Finite-Lived Intangible Assets, Gross	$ 6,400,000	$ 6,400,000
Total	$ 1,534,224
Other [Member] | Maximum [Member]
Amortization Period	13 years
Other [Member] | Minimum [Member]
Amortization Period	5 years

Identifiable Intangible Asset55

Identifiable Intangible Assets, net (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Amortization of Intangible Assets	$ 2,984,259	$ 3,075,244	$ 2,842,885
Cost of Sales [Member]
Amortization of Intangible Assets	2,209,259	2,300,244	2,009,472
Selling, General and Administrative Expenses [Member]
Amortization of Intangible Assets	$ 775,000	$ 775,000	$ 833,413

Identifiable Intangible Asset56

Identifiable Intangible Assets, net (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 2,984,259	$ 3,075,244	$ 2,842,885
Weighted Average Useful Life	3 years 3 months 18 days
Estimated amortization expense for years ending December 31,
2,016	$ 2,836,178
2,017	2,491,595
2,018	2,294,509
2,019	1,564,618
2,020	480,151
Thereafter	164,194
Total	9,831,245	12,815,504
Product license rights [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 1,103,544	1,194,529	908,758
Weighted Average Useful Life	4 years 2 months 12 days
Estimated amortization expense for years ending December 31,
2,016	$ 1,104,213
2,017	1,104,213
2,018	1,104,213
2,019	1,017,534
2,020	315,151
Thereafter	32,887
Total	4,678,211
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 775,000	775,000	833,413
Weighted Average Useful Life	2 years
Estimated amortization expense for years ending December 31,
2,016	$ 626,250
2,017	281,667
2,018	165,000
2,019	165,000
2,020	165,000
Thereafter	131,307
Total	1,534,224
Developed technology and supply agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 1,105,715	$ 1,105,715	$ 1,100,714
Weighted Average Useful Life	3 years 3 months 18 days
Estimated amortization expense for years ending December 31,
2,016	$ 1,105,715
2,017	1,105,715
2,018	1,025,296
2,019	382,084
2,020	0
Thereafter	0
Total	$ 3,618,810

Accrued Expenses and Other Li57

Accrued Expenses and Other Liabilities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accrued compensation and related taxes	$ 2,390,855	$ 2,845,250
Liabilities related to restructuring (Note 4)	2,079,037	0
Accrued sales incentives and other fees	613,186	557,918
Accrued royalties	444,563	463,823
Accrued Canadian sales rebate, net (Note 16)	237,141	633,162
Other	1,940,936	1,544,058
Total accrued expenses and other liabilities	7,705,718	6,044,211
Less current portion	(6,691,340)	(5,522,853)	[1]
Long term liabilities	$ 1,014,378	$ 521,358
[1]	Reclassified for discontinued operations. See note 3.

Stockholders' Equity (Details)

Stockholders' Equity (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Class of Warrant or Right [Line Items]
Number of Warrants	1,755,330
Series R [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right Expiration Date	Jun. 22, 2016
Number of Warrants	1,705,330
Exercise Price | $ / shares | $ / shares	$ 9.90
Series S [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right Expiration Date	Jan. 14, 2019
Number of Warrants	50,000
Exercise Price | $ / shares | $ / shares	$ 11.81

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Weighted Average Assumptions Used In Estimation Of Fair Value Of Option Awards [Line Items]
Risk-free interest rate	1.63%	1.79%	1.22%
Volatility factor	46.10%	63.20%	69.90%
Dividend yield	0.00%	0.00%	0.00%
Expected option life (years)	5 years 9 months 22 days	5 years 9 months 14 days	6 years 1 month 20 days

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Number of Shares
Outstanding Begining	2,166,959	1,814,233	1,639,985
Granted	609,090	637,383	421,480
Forfeited	(280,302)	(116,765)	(36,878)
Exercised	(129,018)	(145,053)	(184,824)
Expired	(64,969)	(22,839)	(25,530)
Outstanding Ending	2,301,760	2,166,959	1,814,233
Exercisable at December 31, 2015	1,855,931
Expected to vest at December 31, 2015	2,278,742
Weighted Average Exercise Price
Outstanding Begining	$ 9.03	$ 7.67	$ 6.38
Granted	8.54	12.98	12.14
Forfeited	9.96	12.48	10.99
Exercised	4.19	6.42	5.5
Expired	9.87	10.70	13.16
Outstanding Ending	9.04	$ 9.03	$ 7.67
Exercisable at December 31, 2015	8.65
Expected to vest at December 31, 2015	$ 9.07
Weighted Average Remaining Contractual Life
Outstanding	6 years 6 months	6 years 6 months	6 years 4 months 24 days

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3) - Employee Stock Option [Member] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 2,210,465	$ 2,998,455	$ 2,349,134
Discontinued Operations [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	37,397	194,427	165,581
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	168,800	178,899	95,726
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 2,004,268	$ 2,625,129	$ 2,087,827

Stockholders' Equity (Details 4

Stockholders' Equity (Details 4) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Number of Shares
Unvested Beginning	651,883	720,550	786,900
Granted	124,500	101,100	79,300
Vested	(185,038)	(148,050)	(145,650)
Cancelled	(438,595)	(21,717)
Unvested Ending	152,750	651,883	720,550
Weighted Average Fair Value
Unvested Beginning	$ 8.47	$ 9.03	$ 8.78
Granted	7.39	10.05	13.65
Vested	10.43	11.86	10.18
Cancelled	7.30	12.78
Unvested Ending	$ 8.59	$ 8.47	$ 9.03

Stockholders' Equity (Details 5

Stockholders' Equity (Details 5)	Dec. 31, 2015shares
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	6,753,202
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	152,750
Warrant [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	1,755,330
Employee Stock Option [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	2,301,760
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	73,332
Other Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	49,782
Common Stock Equivalents Available For Grant [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	2,420,248

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	May. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	May. 20, 2014	Dec. 31, 2012
Stockholders Equity [Line Items]
Convertible Preferred Stock Additional Shares		49,782
Proceeds From Stock Option And Warrant Exercises		$ 1,992,463	$ 2,270,714	$ 2,817,001
Preferred Stock, Shares Outstanding		73,332	73,332
Convertible Preferred Stock, Shares Issued upon Conversion		123,114
Stock Issued During Period, Shares, Period Increase (Decrease)			7,972,132	822,348
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		185,038	148,050	145,650
Stock Issued During Period Shares Stock Warrants Exercised			264,611	421,465
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised		326,933	266,188	624,882
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures			50,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate		1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		609,090	637,383	421,480
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 519,604	$ 684,060	$ 1,286,818
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 1,670,237
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 6 months
Shares withheld for minimum payroll taxes		$ 168,946	$ 300,070	$ 228,149
Common Stock, Capital Shares Reserved for Future Issuance		6,753,202
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		129,018	145,053	184,824
Stock Issued During Period, Value, New Issues			$ 80,616,032	$ 0
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs			$ 5,633,968
Common Stock, Shares Authorized		50,000,000	50,000,000			25,000,000
Stock Issued During Period Shares Preferred Stock Ratio Adjustments Per Previous Shareholder			1,397
Stock Issued During Period, Shares, Issued for Services				4,450
Stock Issued During Period Shares For Stock Options Exercised		77,254	87,040	135,390
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		$ 182,230
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		$ 179,126
Share Price		$ 4.57
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued				5,000
Proceeds from Issuance of Common Stock		$ 0	$ 80,616,032	$ 0
Chief Executive Officer [Member]
Stockholders Equity [Line Items]
Allocated Share-based Compensation Expense		$ 114,573
Minimum [Member]
Stockholders Equity [Line Items]
Common Stock, Shares Authorized					35,000,000
Maximum [Member]
Stockholders Equity [Line Items]
Common Stock, Shares Authorized					50,000,000
Common Stock [Member]
Stockholders Equity [Line Items]
Stock Issued During Period Shares Stock Options And Warrants Exercised		404,187	351,651	556,855
Proceeds From Stock Option And Warrant Exercises		$ 4,042	$ 3,516	$ 5,568
Stock Issued During Period, Shares, Period Increase (Decrease)		557,667
Stock Issued During Period, Shares, Restricted Stock Award, Gross		153,480
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		185,038
Shares withheld for minimum payroll taxes		$ 0	$ 0	$ 0
Stock Issued During Period Shares Preferred Stock Ratio Adjustments			1,397	140,086
Stock Issued During Period, Value, New Issues			$ 75,000	$ 45
Stock Issued During Period, Shares, New Issues		7,500,000	7,500,000	4,450
Shares Issued, Price Per Share		$ 11.50
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total		153,480	119,084	120,957
Preferred Stock [Member]
Stockholders Equity [Line Items]
Stock Issued During Period Shares Preferred Stock Ratio Adjustments				140,086
Series A Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred Stock, Shares Outstanding		18,598
Preferred Stock, Liquidation Preference Per Share		$ 32
Series B Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred Stock, Shares Outstanding		54,734
Preferred Stock, Liquidation Preference Per Share		$ 48
Selling, General and Administrative Expenses [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost		$ 70,670
Goods and Services Exchanged for Equity Instrument [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		451,090	452,057	300,880
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 3.82	$ 7.63	$ 8.30
Employee Stock Option [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	15,000
Allocated Share-based Compensation Expense		$ 2,210,465	$ 2,998,455	$ 2,349,134
Common Stock, Capital Shares Reserved for Future Issuance		2,420,248
Common Stock, Shares Authorized		6,000,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options, Beginning Balance		2,301,760
Proceeds from Issuance of Common Stock		$ 119,520	288,553	407,198
Employee Stock Option [Member] | Selling, General and Administrative Expenses [Member]
Stockholders Equity [Line Items]
Allocated Share-based Compensation Expense		$ 2,004,268	$ 2,625,129	$ 2,087,827
Performance Shares [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		158,000	185,326	120,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 3.82	$ 7.63	$ 8.30
Restricted Stock Units (RSUs) [Member]
Stockholders Equity [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 811,850
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		6 months 29 days
Shares Paid for Tax Withholding for Share Based Compensation		31,558	28,966	24,693
Shares withheld for minimum payroll taxes		$ 168,946	$ 300,070	$ 228,149
Common Stock, Capital Shares Reserved for Future Issuance		152,750
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total		152,750
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested		$ 698,068
Restricted Stock Units (RSUs) [Member] | Selling, General and Administrative Expenses [Member]
Stockholders Equity [Line Items]
Allocated Share-based Compensation Expense		$ 2,388,101	$ 2,593,239	2,634,340
Prior Service Awards [Member]
Stockholders Equity [Line Items]
Allocated Share-based Compensation Expense				$ 337,422
Prior Service Awards [Member] | Retiring Director [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		36 months	24 years	36 years
Allocated Share-based Compensation Expense			$ 48,536
Prior Service Awards [Member] | Former director [Member]
Stockholders Equity [Line Items]
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued				4,450
Series N [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised		100,000
Series O [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised		93,600		53,667
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			132,666
Series P [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised				2,508
Series Q [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised		133,333
Series R [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			127,272
Series L [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			6,250
Series K [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised				367,814
Series J [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised				200,893

Accumulated Other Comprehensi65

Accumulated Other Comprehensive Income (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Beginning, Balance	$ 911,563	$ 1,080,148	$ 1,588,888
Current period - other comprehensive (loss) income	4,361,345	(168,585)	(508,740)
Ending, Balance	5,272,908	911,563	1,080,148
Foreign Currency Translation Adjustments [Member]
Beginning, Balance	1,001,298	1,218,008	1,588,888
Current period - other comprehensive (loss) income	(445,360)	(216,710)	(370,880)
Ending, Balance	555,938	1,001,298	1,218,008
Unrealized (Loss) Gain on Equity Securities [Member]
Beginning, Balance	(89,735)	(137,860)	0
Current period - other comprehensive (loss) income	4,806,705	48,125	(137,860)
Ending, Balance	$ 4,716,970	$ (89,735)	$ (137,860)

Operating Segments (Details)

Operating Segments (Details) - USD ($)	3 Months Ended										12 Months Ended
	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014		Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014		Dec. 31, 2013
Segment Reporting Information [Line Items]
Net sales	$ 20,250,000	[1]	$ 22,169,000	$ 22,556,000	$ 19,499,000	$ 22,874,000	[1]	$ 20,169,000	$ 20,916,000	$ 19,787,000	$ 84,474,284	$ 83,745,680	[2]	$ 79,710,980	[2]
Gross profit	8,392,000	[1]	8,436,000	8,371,000	7,535,000	8,994,000	[1]	6,359,000	7,845,000	6,912,000	32,734,175	30,109,935	[2]	29,390,474	[2]
Direct expense											(37,840,739)	(36,113,488)		(26,463,186)
Segment contribution											(5,106,564)	(6,003,553)		2,927,288
Indirect expenses											(15,260,099)	(14,841,062)		(15,456,784)
Net loss from continuing operations	(4,739,000)	[1]	$ (4,111,000)	$ (5,026,000)	$ (6,490,000)	(3,452,000)	[1]	$ (6,914,000)	$ (4,359,000)	$ (6,120,000)	(20,366,663)	(20,844,615)	[2]	(12,529,496)	[2]
Restructuring And Other Charges											2,458,555
Depreciation											925,597	867,614		878,151
Amortization											2,984,259	3,075,244		2,842,885
Capital expenditures											1,811,325	1,732,523		695,776
Equipment and improvements, net	4,129,208					3,614,439	[2]				4,129,208	3,614,439	[2]
Identifiable intangible assets, net	9,831,245					12,815,504					9,831,245	12,815,504
Goodwill	13,457,693					13,457,693	[2]				13,457,693	13,457,693	[2]
Total assets	114,780,155					139,290,466	[2]				114,780,155	139,290,466	[2]
Advanced Wound Care [Member]
Segment Reporting Information [Line Items]
Net sales											41,782,144	38,110,851		33,928,535
Gross profit											21,040,514	18,170,944		16,837,797
Direct expense											(32,684,540)	(30,919,972)		(21,404,045)
Segment contribution											(11,644,026)	(12,749,028)		(4,566,248)
Restructuring And Other Charges											722,810
Depreciation											512,862	464,686		477,118
Amortization											2,699,259	2,789,763		2,557,805
Capital expenditures											1,475,994	918,673		437,169
Equipment and improvements, net	2,649,208					2,274,254					2,649,208	2,274,254
Identifiable intangible assets, net	9,379,938					12,079,197					9,379,938	12,079,197
Goodwill	6,337,967					6,337,967					6,337,967	6,337,967
Total assets	34,794,250					35,033,245					34,794,250	35,033,245
Traditional Wound Care [Member]
Segment Reporting Information [Line Items]
Net sales											42,692,140	45,634,829		45,782,445
Gross profit											11,693,661	11,938,991		12,552,677
Direct expense											(5,156,199)	(5,193,516)		(5,059,141)
Segment contribution											6,537,462	6,745,475		7,493,536
Restructuring And Other Charges											105,075
Depreciation											223,102	226,830		264,841
Amortization											285,000	285,481		285,080
Capital expenditures											75,441	198,374		24,193
Equipment and improvements, net	701,548					598,781					701,548	598,781
Identifiable intangible assets, net	451,307					736,307					451,307	736,307
Goodwill	7,119,726					7,119,726					7,119,726	7,119,726
Total assets	23,956,132					20,475,555					23,956,132	20,475,555
Other [Member]
Segment Reporting Information [Line Items]
Net sales											0	0		0
Gross profit											0	0		0
Direct expense											0	0		0
Segment contribution											0	0		0
Indirect expenses											(15,260,099)	(14,841,062)		(15,456,784)
Restructuring And Other Charges											1,630,670
Depreciation											189,633	176,098		136,192
Amortization											0	0		0
Capital expenditures											259,890	603,050		$ 234,414
Equipment and improvements, net	778,452					725,619					778,452	725,619
Identifiable intangible assets, net	0					0					0	0
Goodwill	0					0					0	0
Total assets	$ 56,029,773					$ 83,781,666					$ 56,029,773	$ 83,781,666
[1]	In the 4th quarter of 2015, the Company implemented a restructuring plan and incurred other charges. See Note 4.
[2]	Reclassified for discontinued operations. See note 3.

Operating Segments (Details 1)

Operating Segments (Details 1) - USD ($)	3 Months Ended										12 Months Ended
	Dec. 31, 2015		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014		Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014		Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 20,250,000	[1]	$ 22,169,000	$ 22,556,000	$ 19,499,000	$ 22,874,000	[1]	$ 20,169,000	$ 20,916,000	$ 19,787,000	$ 84,474,284	$ 83,745,680	[2]	$ 79,710,980	[2]
Gross profit	8,392,000	[1]	$ 8,436,000	$ 8,371,000	$ 7,535,000	8,994,000	[1]	$ 6,359,000	$ 7,845,000	$ 6,912,000	32,734,175	30,109,935	[2]	29,390,474	[2]
Equipment and improvements, net	4,129,208					3,614,439	[2]				4,129,208	3,614,439	[2]
Identifiable intangible assets, net	9,831,245					12,815,504	[2]				9,831,245	12,815,504	[2]
Goodwill	13,457,693					13,457,693	[2]				13,457,693	13,457,693	[2]
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales											65,613,639	63,324,527		61,234,755
Gross profit											24,907,022	25,415,410		23,956,554
Equipment and improvements, net	1,142,655					1,204,152					1,142,655	1,204,152
Identifiable intangible assets, net	9,831,245					12,815,504					9,831,245	12,815,504
Goodwill	13,457,693					13,457,693					13,457,693	13,457,693
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales											9,701,712	11,859,900		11,084,430
Gross profit											4,263,083	1,134,949		2,371,054
Equipment and improvements, net	2,859,316					2,203,015					2,859,316	2,203,015
Identifiable intangible assets, net	0					0					0	0
Goodwill	0					0					0	0
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales											9,158,933	8,561,253		7,391,795
Gross profit											3,564,070	3,559,576		$ 3,062,866
Equipment and improvements, net	127,237					207,272					127,237	207,272
Identifiable intangible assets, net	0					0					0	0
Goodwill	$ 0					$ 0					$ 0	$ 0
[1]	In the 4th quarter of 2015, the Company implemented a restructuring plan and incurred other charges. See Note 4.
[2]	Reclassified for discontinued operations. See note 3.

Operating Segments (Details Tex

Operating Segments (Details Textual)	12 Months Ended
	Dec. 31, 2015
Concentration Risk [Line Items]
Number of Operating Segments	2

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014		Dec. 31, 2013
Income Tax Contingency [Line Items]
Domestic	$ (23,246,881)	$ (18,927,332)		$ (11,710,997)
Foreign	635,503	(2,068,331)		(658,388)
Loss before income taxes from continuing operations	$ (22,611,378)	$ (20,995,663)	[1]	$ (12,369,385)	[1]
[1]	Reclassified for discontinued operations. See note 3.

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014		Dec. 31, 2013
Current:
Federal	$ 0	$ 0		$ 0
State	0	0		5,365
Foreign	481,241	(165,953)		22,590
Total current	481,241	(165,953)		27,955
Deferred:
Federal	(2,327,987)	124,316		149,108
State	(493,065)	(105,575)		(34,143)
Foreign	95,096	(3,836)		17,191
Total deferred	(2,725,996)	14,905		132,156
Income tax (benefit) provision from continuing operations	$ (2,244,715)	$ (151,048)	[1]	$ 160,111	[1]
[1]	Reclassified for discontinued operations. See note 3.

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014		Dec. 31, 2013
Income Tax Reconciliation
Tax benefit at federal statutory rate	34.00%	34.00%		34.00%
State tax, net of federal benefit	3.00%	2.70%		2.90%
Foreign tax	(0.10%)	(1.00%)		(0.60%)
Nondeductible expenses	(4.90%)	(5.80%)		(5.20%)
Other	(4.50%)	9.10%		0.40%
Change in valuation allowance	(17.50%)	(38.30%)		(32.80%)
Income taxes	10.00%	0.70%		(1.30%)
Income Tax Rate Reconciliation
Tax benefit at federal statutory rate	$ (7,687,869)	$ (7,138,525)		$ (4,205,591)
State tax, net of federal benefit	(674,428)	(557,058)		(354,144)
Foreign tax	30,389	199,505		74,612
Nondeductible expenses	1,118,747	1,215,047		637,797
Other	1,025,238	(1,914,781)		(50,860)
Change in valuation allowance	3,943,208	8,044,764		4,058,297
Income tax (benefit) provision	$ (2,244,715)	$ (151,048)	[1]	$ 160,111	[1]
[1]	Reclassified for discontinued operations. See note 3.

Income Taxes (Details 3)

Income Taxes (Details 3) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net operating loss carryforwards	$ 41,857,037	$ 29,384,036
Equity based compensation	782,880	2,103,130
Allowance for sales deductions	261,558	198,625
Amortization of identified intangibles	2,092,885	2,047,495
Inventory adjustments	792,834	420,004
Tax Credits	2,617,819	1,786,366
Other	1,217,224	720,203
Deferred tax assets	49,622,237	36,659,859
Deferred tax liabilities:
Prepaid expenses	(197,358)	(185,803)
Goodwill	(1,513,377)	(1,347,378)
Depreciation	(351,112)	(348,135)
Identified intangibles	(1,651,571)	(2,216,271)
Unrealized gain on equity security	(2,857,263)	0
Deferred tax liabilities	(6,570,681)	(4,097,587)
Valuation allowance	(44,856,072)	(34,255,466)
Net deferred tax liabilities	$ (1,804,516)	$ (1,693,194)

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014		Dec. 31, 2013	[1]
Income Taxes [Line Items]
Income tax (benefit) provision	$ (2,244,715)	$ (151,048)	[1]	$ 160,111
Deferred Tax Liabilities, Goodwill	1,513,377	1,347,378
Deferred Tax Assets, Operating Loss Carryforwards, Total	41,857,037	29,384,036
Deferred Tax Liabilities, Gross	6,570,681	$ 4,097,587
Research and development tax credit [Member]
Income Taxes [Line Items]
Tax Credit Carryforward, Amount	2,452,588
Foreign [Member]
Income Taxes [Line Items]
Income tax (benefit) provision	576,337
Tax Credit Carryforward, Amount	165,231
Deferred Tax Liabilities, Gross	290,763
US [Member]
Income Taxes [Line Items]
Income tax (benefit) provision	2,821,052
Unrealized Gain (Loss) on Securities	2,880,683
Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Goodwill	166,000
Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Intangible Assets	106,369
Deferred Tax Liabilities, Goodwill	1,513,753
Deferred Tax Assets, Operating Loss Carryforwards, Total	$ 111,961,000
[1]	Reclassified for discontinued operations. See note 3.

Retirement Benefits (Details Te

Retirement Benefits (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%	100.00%	100.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4.00%	4.00%	4.00%
Defined Benefit Plan, Contributions by Employer	$ 599,447	$ 505,769	$ 295,735
CanadianSubsidiary [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%	100.00%	100.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4.00%	4.00%	4.00%
Defined Benefit Plan, Contributions by Employer	$ 146,102	$ 152,551	$ 133,319

Commitments and Contingencies75

Commitments and Contingencies (Details)	Dec. 31, 2015USD ($)
Operating Leased Assets [Line Items]
2,016	$ 1,627,939
2,017	1,415,377
2,018	937,226
2,019	470,050
2,020	276,901
Thereafter	53,038
Net minimum future rental payments	$ 4,780,531

Commitments and Contingencies76

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012	Jan. 14, 2014
Commitments and Contingencies [Line Items]
Royalty Expense		$ 2,185,161	$ 1,853,187		$ 1,741,742
Operating Leases, Rent Expense, Net, Total		1,625,443	1,565,307		1,227,718
Deferred Rent Credit, Noncurrent		427,455	521,358
Available-for-sale Equity Securities, Amortized Cost Basis			8,483,693		8,483,693
Inventory, Net, Total		20,690,706	13,280,940	[1]
Comvita Agreement [Member]
Commitments and Contingencies [Line Items]
Related Party Transaction, Purchases from Related Party		4,014,969	2,203,992		2,266,964
Royalty Expense		1,336,559	1,357,040		1,240,818
Due to Related Parties		506,795	625,947
Licensing Agreements Milestone Payments Maximum		20,000,000
Available-for-sale Equity Securities, Amortized Cost Basis			8,483,693		8,483,693
Reimbursement Revenue			125,000
BioD Agreement [Member]
Commitments and Contingencies [Line Items]
Royalty Expense		314,545	66,202
Licensing Agreements Milestone Payments Maximum		19,750,000
License Agreement Milestone Sales		2,000,000
Other Commitment, Total							$ 2,000,000
License Costs	$ 1,250,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 11.81
Warrants and Rights Outstanding	$ 129,750
Finite-Lived License Agreements, Gross	$ 1,379,750
BioD Agreement [Member] | Immediately [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
BioD Agreement [Member] | Milestones [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	75.00%
QMT Agreement [Member]
Commitments and Contingencies [Line Items]
Royalty Expense		178,546	$ 178,476		$ 202,377
Licensing Agreements Milestone Payments Maximum		3,500,000
License Costs						$ 1,300,000
NCIC International Agreement [Member]
Commitments and Contingencies [Line Items]
Licensing Agreements Payments		100,000
Licensing Agreements Milestone Payments Maximum		1,000,000
Canadian Distribution Agreement [Member]
Commitments and Contingencies [Line Items]
Inventory, Net, Total		$ 2,600,000
[1]	Reclassified for discontinued operations. See note 3.

Quarterly Consolidated Financ77

Quarterly Consolidated Financial Data (Unaudited) (Details) - USD ($)	3 Months Ended										12 Months Ended
	Dec. 31, 2015	[1]	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	[1]	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014		Dec. 31, 2013	[2]
Net sales	$ 20,250,000		$ 22,169,000	$ 22,556,000	$ 19,499,000	$ 22,874,000		$ 20,169,000	$ 20,916,000	$ 19,787,000	$ 84,474,284	$ 83,745,680	[2]	$ 79,710,980
Gross profit	8,392,000		8,436,000	8,371,000	7,535,000	8,994,000		6,359,000	7,845,000	6,912,000	32,734,175	30,109,935	[2]	29,390,474
Loss from continuing operations, net of taxes	(4,739,000)		(4,111,000)	(5,026,000)	(6,490,000)	(3,452,000)		(6,914,000)	(4,359,000)	(6,120,000)	(20,366,663)	(20,844,615)	[2]	(12,529,496)
Loss from discontinued operations, net of taxes	(4,510,000)		(4,852,000)	(4,260,000)	(4,119,000)	(6,115,000)		(4,334,000)	(4,328,000)	(4,150,000)	(17,741,000)	(18,927,000)
Net loss	$ (9,249,000)		$ (8,963,000)	$ (9,286,000)	$ (10,609,000)	$ (9,567,000)		$ (11,248,000)	$ (8,687,000)	$ (10,270,000)	$ (38,107,480)	$ (39,771,555)	[2]	$ (23,964,053)
Net loss per common share - basic and diluted
Continuing operations	$ (0.18)		$ (0.16)	$ (0.19)	$ (0.26)	$ (0.14)		$ (0.28)	$ (0.17)	$ (0.28)	$ (0.79)	$ (0.85)	[2]	$ (0.73)
Discontinued operations	(0.18)		(0.19)	(0.17)	(0.16)	(0.24)		(0.17)	(0.17)	(0.18)	(0.69)	(0.77)	[2]	$ (0.67)
Total net loss per common share - basic and diluted	$ (0.36)		$ (0.35)	$ (0.36)	$ (0.42)	$ (0.38)		$ (0.45)	$ (0.34)	$ (0.46)	$ (1.48)	$ (1.62)
[1]	In the 4th quarter of 2015, the Company implemented a restructuring plan and incurred other charges. See Note 4.
[2]	Reclassified for discontinued operations. See note 3.